<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Mol Autism</journal-id>
<journal-id journal-id-type="iso-abbrev">Mol Autism</journal-id>
<journal-title-group>
<journal-title>Molecular Autism</journal-title>
</journal-title-group>
<issn pub-type="epub">2040-2392</issn>
<publisher>
<publisher-name>BioMed Central</publisher-name>
<publisher-loc>London</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">29090079</article-id>
<article-id pub-id-type="pmc">5655854</article-id>
<article-id pub-id-type="publisher-id">172</article-id>
<article-id pub-id-type="doi">10.1186/s13229-017-0172-6</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Research</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Prospective investigation of FOXP1 syndrome</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" equal-contrib="yes">
<name>
<surname>Siper</surname>
<given-names>Paige M.</given-names>
</name>
<address>
<email>paige.siper@mssm.edu</email>
</address>
<xref ref-type="aff" rid="Aff1">1</xref>
<xref ref-type="aff" rid="Aff8">8</xref>
</contrib>
<contrib contrib-type="author" equal-contrib="yes">
<name>
<surname>De Rubeis</surname>
<given-names>Silvia</given-names>
</name>
<address>
<email>silvia.derubeis@mssm.edu</email>
</address>
<xref ref-type="aff" rid="Aff1">1</xref>
<xref ref-type="aff" rid="Aff8">8</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Trelles</surname>
<given-names>Maria del Pilar</given-names>
</name>
<address>
<email>pilar.trelles@mssm.edu</email>
</address>
<xref ref-type="aff" rid="Aff1">1</xref>
<xref ref-type="aff" rid="Aff8">8</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Durkin</surname>
<given-names>Allison</given-names>
</name>
<address>
<email>allison.durkin@mssm.edu</email>
</address>
<xref ref-type="aff" rid="Aff1">1</xref>
<xref ref-type="aff" rid="Aff8">8</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Di Marino</surname>
<given-names>Daniele</given-names>
</name>
<address>
<email>daniele.di.marino@usi.ch</email>
</address>
<xref ref-type="aff" rid="Aff2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Muratet</surname>
<given-names>François</given-names>
</name>
<address>
<email>muratet.francois@orange.fr</email>
</address>
<xref ref-type="aff" rid="Aff1">1</xref>
<xref ref-type="aff" rid="Aff8">8</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Frank</surname>
<given-names>Yitzchak</given-names>
</name>
<address>
<email>yitzchak.frank@mssm.edu</email>
</address>
<xref ref-type="aff" rid="Aff1">1</xref>
<xref ref-type="aff" rid="Aff8">8</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Lozano</surname>
<given-names>Reymundo</given-names>
</name>
<address>
<email>reymundo.lozano@mssm.edu</email>
</address>
<xref ref-type="aff" rid="Aff3">3</xref>
<xref ref-type="aff" rid="Aff8">8</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Eichler</surname>
<given-names>Evan E.</given-names>
</name>
<address>
<email>eee@gs.washington.edu</email>
</address>
<xref ref-type="aff" rid="Aff4">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Kelly</surname>
<given-names>Morgan</given-names>
</name>
<address>
<email>mkelly26@uw.edu</email>
</address>
<xref ref-type="aff" rid="Aff5">5</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Beighley</surname>
<given-names>Jennifer</given-names>
</name>
<address>
<email>beighj@uw.edu</email>
</address>
<xref ref-type="aff" rid="Aff5">5</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Gerdts</surname>
<given-names>Jennifer</given-names>
</name>
<address>
<email>jvarley@uw.edu</email>
</address>
<xref ref-type="aff" rid="Aff5">5</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Wallace</surname>
<given-names>Arianne S.</given-names>
</name>
<address>
<email>as77@uw.edu</email>
</address>
<xref ref-type="aff" rid="Aff5">5</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Mefford</surname>
<given-names>Heather C.</given-names>
</name>
<address>
<email>hmefford@uw.edu</email>
</address>
<xref ref-type="aff" rid="Aff5">5</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Bernier</surname>
<given-names>Raphael A.</given-names>
</name>
<address>
<email>rab2@uw.edu</email>
</address>
<xref ref-type="aff" rid="Aff5">5</xref>
</contrib>
<contrib contrib-type="author" corresp="yes" equal-contrib="yes">
<name>
<surname>Kolevzon</surname>
<given-names>Alexander</given-names>
</name>
<address>
<email>alexander.kolevzon@mssm.edu</email>
</address>
<xref ref-type="aff" rid="Aff6">6</xref>
<xref ref-type="aff" rid="Aff8">8</xref>
</contrib>
<contrib contrib-type="author" corresp="yes" equal-contrib="yes">
<name>
<surname>Buxbaum</surname>
<given-names>Joseph D.</given-names>
</name>
<address>
<email>joseph.buxbaum@mssm.edu</email>
</address>
<xref ref-type="aff" rid="Aff7">7</xref>
<xref ref-type="aff" rid="Aff8">8</xref>
</contrib>
<aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 0670 2351</institution-id><institution-id institution-id-type="GRID">grid.59734.3c</institution-id><institution>Department of Psychiatry, </institution><institution>Icahn School of Medicine at Mount Sinai, </institution></institution-wrap>New York, NY USA </aff>
<aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2203 2861</institution-id><institution-id institution-id-type="GRID">grid.29078.34</institution-id><institution>Department of Informatics, </institution><institution>Institute of Computational Science, Università della Svizzera Italiana, </institution></institution-wrap>Lugano, Switzerland </aff>
<aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 0670 2351</institution-id><institution-id institution-id-type="GRID">grid.59734.3c</institution-id><institution>Department of Genetics and Genomic Sciences, Seaver Autism Center for Research and Treatment, Department of Psychiatry, Department of Pediatrics, </institution><institution>Icahn School of Medicine at Mount Sinai, </institution></institution-wrap>New York, NY USA </aff>
<aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ISNI">0000000122986657</institution-id><institution-id institution-id-type="GRID">grid.34477.33</institution-id><institution>Department of Genome Sciences, </institution><institution>University of Washington, </institution></institution-wrap>Seattle, WA USA </aff>
<aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ISNI">0000000122986657</institution-id><institution-id institution-id-type="GRID">grid.34477.33</institution-id><institution>Department of Psychiatry, </institution><institution>University of Washington, </institution></institution-wrap>Seattle, WA USA </aff>
<aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 0670 2351</institution-id><institution-id institution-id-type="GRID">grid.59734.3c</institution-id><institution>Department of Psychiatry, Department of Pediatrics, Friedman Brain Institute, Mindich Child Health and Development Institute, </institution><institution>Icahn School of Medicine at Mount Sinai, </institution></institution-wrap>New York, NY USA </aff>
<aff id="Aff7"><label>7</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 0670 2351</institution-id><institution-id institution-id-type="GRID">grid.59734.3c</institution-id><institution>Department of Psychiatry, Department of Genetics and Genomic Sciences, Department of Neuroscience, Friedman Brain Institute, Mindich Child Health and Development Institute, </institution><institution>Icahn School of Medicine at Mount Sinai, </institution></institution-wrap>New York, NY USA </aff>
<aff id="Aff8"><label>8</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 0670 2351</institution-id><institution-id institution-id-type="GRID">grid.59734.3c</institution-id><institution>Seaver Autism Center for Research and Treatment, </institution><institution>Icahn School of Medicine at Mount Sinai, </institution></institution-wrap>New York, USA </aff>
</contrib-group>
<pub-date pub-type="epub">
<day>24</day>
<month>10</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>24</day>
<month>10</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="collection">
<year>2017</year>
</pub-date>
<volume>8</volume>
<elocation-id>57</elocation-id>
<history>
<date date-type="received">
<day>4</day>
<month>7</month>
<year>2017</year>
</date>
<date date-type="accepted">
<day>27</day>
<month>9</month>
<year>2017</year>
</date>
</history>
<permissions>
<copyright-statement>© The Author(s). 2017</copyright-statement>
<license license-type="OpenAccess">
<license-p>
<bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p>
</license>
</permissions>
<abstract id="Abs1">
<sec>
<title>Background</title>
<p id="Par1">Haploinsufficiency of the forkhead-box protein P1 (<italic>FOXP1</italic>) gene leads to a neurodevelopmental disorder termed FOXP1 syndrome. Previous studies in individuals carrying <italic>FOXP1</italic> mutations and deletions have described the presence of autism spectrum disorder (ASD) traits, intellectual disability, language impairment, and psychiatric features. The goal of the present study was to comprehensively characterize the genetic and clinical spectrum of FOXP1 syndrome. This is the first study to prospectively examine the genotype-phenotype relationship in multiple individuals with FOXP1 syndrome, using a battery of standardized clinical assessments.</p>
</sec>
<sec>
<title>Methods</title>
<p id="Par2">Genetic and clinical data was obtained and analyzed from nine children and adolescents between the ages of 5–17 with mutations in <italic>FOXP1</italic>. Phenotypic characterization included gold standard ASD testing and norm-referenced measures of cognition, adaptive behavior, language, motor, and visual-motor integration skills. In addition, psychiatric, medical, neurological, and dysmorphology examinations were completed by a multidisciplinary team of clinicians. A comprehensive review of reported cases was also performed. All missense and in-frame mutations were mapped onto the three-dimensional structure of DNA-bound FOXP1.</p>
</sec>
<sec>
<title>Results</title>
<p id="Par3">We have identified nine de novo mutations, including three frameshift, one nonsense, one mutation in an essential splice site resulting in frameshift and insertion of a premature stop codon, three missense, and one in-frame deletion. Reviewing prior literature, we found seven instances of recurrent mutations and another 34 private mutations. The majority of pathogenic missense and in-frame mutations, including all four missense mutations in our cohort, lie in the DNA-binding domain. Through structural analyses, we show that the mutations perturb amino acids necessary for binding to the DNA or interfere with the domain swapping that mediates FOXP1 dimerization. Individuals with FOXP1 syndrome presented with delays in early motor and language milestones, language impairment (expressive language &gt; receptive language), ASD symptoms, visual-motor integration deficits, and complex psychiatric presentations characterized by anxiety, obsessive-compulsive traits, attention deficits, and externalizing symptoms. Medical features included non-specific structural brain abnormalities and dysmorphic features, endocrine and gastrointestinal problems, sleep disturbances, and sinopulmonary infections.</p>
</sec>
<sec>
<title>Conclusions</title>
<p id="Par4">This study identifies novel <italic>FOXP1</italic> mutations associated with FOXP1 syndrome, identifies recurrent mutations, and demonstrates significant clustering of missense mutations in the DNA-binding domain. Clinical findings confirm the role <italic>FOXP1</italic> plays in development across multiple domains of functioning. The genetic findings can be incorporated into clinical genetics practice to improve accurate genetic diagnosis of FOXP1 syndrome and the clinical findings can inform monitoring and treatment of individuals with FOXP1 syndrome.</p>
</sec>
<sec>
<title>Electronic supplementary material</title>
<p>The online version of this article (10.1186/s13229-017-0172-6) contains supplementary material, which is available to authorized users.</p>
</sec>
</abstract>
<funding-group>
<award-group>
<funding-source>
<institution>Beatrice and Samuel A. Seaver Foundation</institution>
</funding-source>
</award-group>
<award-group>
<funding-source>
<institution>Private Philanthropy</institution>
</funding-source>
</award-group>
<award-group>
<funding-source>
<institution-wrap>
<institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000025</institution-id>
<institution>National Institute of Mental Health</institution>
</institution-wrap>
</funding-source>
<award-id>MH100047</award-id>
<award-id>MH101221</award-id>
<principal-award-recipient>
<name>
<surname>Bernier</surname>
<given-names>Raphael A.</given-names>
</name>
</principal-award-recipient>
</award-group>
</funding-group>
<custom-meta-group>
<custom-meta>
<meta-name>issue-copyright-statement</meta-name>
<meta-value>© The Author(s) 2017</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
<body>
<sec id="Sec1">
<title>Background</title>
<p id="Par5">Haploinsufficiency of the forkhead-box protein P1 (<italic>FOXP1</italic>) gene has recently been shown to cause a neurodevelopmental disorder with a phenotype characterized by global developmental delay (DD), intellectual disability (ID), speech deficits, mild dysmorphic features, and autism spectrum disorder (ASD) traits [<xref ref-type="bibr" rid="CR1">1</xref>–<xref ref-type="bibr" rid="CR5">5</xref>]. Here, we refer to this disorder as FOXP1 syndrome.</p>
<p id="Par6">Since the first report of a deletion spanning <italic>FOXP1</italic> and three other genes in a child with DD, speech delay, hypertonia, dysmorphic features, contractures and blepharophimosis [<xref ref-type="bibr" rid="CR6">6</xref>], nearly 20 cases have been reported. The identification of deletions limited to <italic>FOXP1</italic> [<xref ref-type="bibr" rid="CR1">1</xref>–<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR8">8</xref>] and of several individuals with loss-of-function and missense variants in <italic>FOXP1</italic> [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR3">3</xref>–<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR10">10</xref>] has delineated <italic>FOXP1</italic> haploinsufficiency as sufficient to produce core features including delayed motor and language milestones, global speech impairment, ID, dysmorphic features, and ASD. Additional <italic>FOXP1</italic> mutations have also emerged from large-scale targeted sequencing or exome and genome sequencing analyses of cohorts with ID [<xref ref-type="bibr" rid="CR11">11</xref>–<xref ref-type="bibr" rid="CR13">13</xref>] or ASD [<xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR15">15</xref>]; however, these studies have provided minimal phenotypic information. <italic>FOXP1</italic> can be among the genes deleted in cases with 3p14 deletion syndrome, a contiguous gene syndrome that also presents with hearing loss, congenital heart defects, and urogenital abnormalities [<xref ref-type="bibr" rid="CR16">16</xref>–<xref ref-type="bibr" rid="CR18">18</xref>]. Interestingly, common variation at the <italic>FOXP1</italic> locus has shown association in a cross-disorder meta-analysis of ASD and genome-wide association studies in schizophrenia [<xref ref-type="bibr" rid="CR19">19</xref>]. Eight additional pathogenic mutations have emerged after the discovery of a de novo mutation in a whole exome sequencing (WES) study on congenital anomalies of the kidney and urinary tract [<xref ref-type="bibr" rid="CR20">20</xref>]. Notably, all individuals have neurodevelopmental phenotypes compatible with FOXP1 syndrome and the majority (6/8) display upper or lower urinary tract defects [<xref ref-type="bibr" rid="CR20">20</xref>].</p>
<p id="Par7">FOXP1 is a transcription factor of the <italic>FOX</italic> gene family, named for the forkhead-box DNA-binding domain present in the gene family [<xref ref-type="bibr" rid="CR21">21</xref>]. The <italic>FOXP</italic> subfamily is comprised of four genes: <italic>FOXP1</italic>, <italic>FOXP2</italic>, <italic>FOXP3</italic>, and <italic>FOXP4</italic>. The closest homolog to <italic>FOXP1</italic>, and the best-known member of the <italic>FOXP</italic> family, is <italic>FOXP2</italic>. In the brains of zebra finch songbirds and humans, Foxp1 and Foxp2 are co-expressed in the GABAergic medium spiny neurons of the striatum [<xref ref-type="bibr" rid="CR22">22</xref>, <xref ref-type="bibr" rid="CR23">23</xref>], a brain region critical for human language, mouse ultrasonic vocalization (USV), and zebra finch vocal imitation. Both genes are important for language production and comprehension. In addition to the speech impairments observed in individuals with FOXP1 syndrome, maternal uniparental disomy of chromosome 7 (reducing <italic>FOXP2</italic> expression) [<xref ref-type="bibr" rid="CR24">24</xref>], <italic>FOXP2</italic> deletions [<xref ref-type="bibr" rid="CR25">25</xref>], and <italic>FOXP2</italic> mutations [<xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR27">27</xref>], all result in childhood apraxia of speech and other speech and language defects. In addition, both <italic>FOXP1</italic> and <italic>FOXP2</italic> are critical during cortical neurogenesis and specification [<xref ref-type="bibr" rid="CR28">28</xref>–<xref ref-type="bibr" rid="CR30">30</xref>]. Constitutive <italic>FOXP1</italic> knockout is embryonically lethal due to a cardiac defect, but brain-specific conditional <italic>FOXP1</italic> null mice display striatal morphological defects, reduced USV (also reported in <italic>FOXP2</italic> mutant mice [<xref ref-type="bibr" rid="CR31">31</xref>]) and social and cognitive deficits [<xref ref-type="bibr" rid="CR23">23</xref>, <xref ref-type="bibr" rid="CR32">32</xref>].</p>
<p id="Par8">Shared and pervasive clinical features in individuals with <italic>FOXP1</italic> deletions and mutations include mild-to-moderate ID, language impairment, and motor delays [<xref ref-type="bibr" rid="CR1">1</xref>–<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR13">13</xref>]. All reported individuals with FOXP1 syndrome displayed speech and language impairment. While delayed, the developmental trajectory of cognitive, language, and motor skills remains unknown. The majority of individuals described in the literature developed a minimum of phrase speech, all individuals were reported to have difficulty with articulation, and language was often limited to phrases or simple sentences [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR5">5</xref>]. Several investigators reported that expressive language is more affected than receptive language [<xref ref-type="bibr" rid="CR1">1</xref>–<xref ref-type="bibr" rid="CR3">3</xref>]; however, these findings were not based on norm-referenced standardized testing.</p>
<p id="Par9">Medical features of individuals with <italic>FOXP1</italic> mutations reported in the literature vary widely and include brain and cardiac malformations, hypotonia, strabismus, and obesity [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR33">33</xref>, <xref ref-type="bibr" rid="CR34">34</xref>]. Dysmorphic features associated with FOXP1 syndrome appear to be mild and inconsistent. Among the most commonly reported dysmorphic features are a prominent forehead, downslanting or short palpebral fissures, and a short nose with a broad tip [<xref ref-type="bibr" rid="CR3">3</xref>]. Other features may include widely spaced eyes, frontal hair upsweep, ptosis, and hypertelorism [<xref ref-type="bibr" rid="CR7">7</xref>]. Behavioral anomalies, including ASD or autistic traits, aggression, anxiety, and obsessive-compulsive symptoms, were present in a majority of reported cases [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR13">13</xref>].</p>
<p id="Par10">To date, no study has prospectively evaluated more than three individuals with FOXP1 syndrome using a battery of standardized measures. The goal of the present study was to comprehensively characterize FOXP1 syndrome by utilizing a multidisciplinary team of biologists and clinicians and objective assessments to prospectively evaluate a cohort of children and adolescents with mutations in the <italic>FOXP1</italic> gene. We also characterize one individual with a duplication of 8.4 Mb spanning <italic>FOXP1</italic> and 47 additional genes, which has not previously been described and remains of unknown clinical significance (Additional file <xref ref-type="media" rid="MOESM1">1</xref>). Evaluating genetic results in conjunction with a robust battery of clinical assessments will better elucidate the genotype-phenotype relationship in this recently described syndrome, while functional dissection of mutations will provide insights into the pathobiological mechanisms underlying the FOXP1 syndrome.</p>
</sec>
<sec id="Sec2">
<title>Methods</title>
<sec id="Sec3">
<title>Participants</title>
<p id="Par11">Phenotypic characterization was completed in nine children and adolescents (seven female) with mutations in <italic>FOXP1</italic> and one female with a large duplication spanning <italic>FOXP1</italic> (Additional file <xref ref-type="media" rid="MOESM1">1</xref>). Individuals were between the ages of 5–17 (mean ± SD = 11.1 ± 3.6). Evaluations were completed at the Seaver Autism Center for Research and Treatment at the Icahn School of Medicine at Mount Sinai (<italic>n</italic> = 6, subjects S1-S6) and at the Center on Human Development and Disability at the University of Washington (<italic>n</italic> = 4, subjects W1-W4). Comprehensive medical, neurological, dysmorphology, and neuropsychological evaluations were completed by teams of child and adolescent psychiatrists, clinical psychologists, neurologists, and clinical geneticists. A battery of standardized assessments was used to examine ASD symptomatology, intellectual functioning, adaptive behavior, receptive and expressive language, fine and gross motor skills, visual-motor integration, and psychiatric features. Individual S2 was previously reported by Lozano et al. (2015) [<xref ref-type="bibr" rid="CR4">4</xref>]. Individual S4 was previously reported by Sollis et al. (2016) (subject 1) [<xref ref-type="bibr" rid="CR5">5</xref>]. Individual W1 was previously reported by O’Roak et al. (2011) (subject 12817.p1) [<xref ref-type="bibr" rid="CR10">10</xref>], but without a clinical description. This study was approved by the Institutional Review Boards of both participating sites. All caregivers provided informed written consent and assent was obtained when appropriate.</p>
</sec>
<sec id="Sec4">
<title>Genetic testing</title>
<p id="Par12">All mutations were validated by Clinical Laboratory Improvement Amendments (CLIA)-certified clinical genetics testing laboratories. The mutation in S1 was identified through clinical WES by the Molecular Genetics Laboratory at the Children’s and Women’s Health Centre in Vancouver. The mutation in S2 was identified as described before [<xref ref-type="bibr" rid="CR4">4</xref>]. The mutation in S3 was detected through clinical WES performed by Baylor Miraca Genetics Laboratories. The mutation in S4 was identified as described before [<xref ref-type="bibr" rid="CR5">5</xref>]. The mutation in S5 was identified through clinical WES by GeneDx. Mutations in individuals S1-S5 were further validated by Sanger sequencing in the laboratory. The mutation in W1 was identified by WES as described before [<xref ref-type="bibr" rid="CR10">10</xref>]. The mutation in W2 was identified by clinical WES performed by the Shodair Children’s Hospital. The mutation in W3 was identified through clinical WES by GeneDx. The mutation in W4 was detected by clinical WES at Victorian Clinical Genetics Services.</p>
<p id="Par13">The Human Genome Variation Society (HGVS) guidelines for mutation nomenclature were used [<xref ref-type="bibr" rid="CR35">35</xref>]. In all tables and figures, the cDNA and amino acid positions were annotated according to the most updated <italic>FOXP1</italic> RefSeq mRNA and protein sequence (NM_032682.5 and NP_116071.2). Nucleotide numbering referring to cDNA uses +1 as the A of the ATG translation initiation codon in the reference sequence, with the initiation codon as codon 1.</p>
<p id="Par14">The following control databases were used: Exome Variant Server (EVS, <ext-link ext-link-type="uri" xlink:href="http://evs.gs.washington.edu/EVS">http://evs.gs.washington.edu/EVS/</ext-link>), Exome Aggregation Consortium (ExAC, <ext-link ext-link-type="uri" xlink:href="http://exac.broadinstitute.org">http://exac.broadinstitute.org</ext-link>), and genome Aggregation Database (gnomAD, <ext-link ext-link-type="uri" xlink:href="http://gnomad.broadinstitute.org">http://gnomad.broadinstitute.org</ext-link>).</p>
</sec>
<sec id="Sec5">
<title>Review of individuals with previously published <italic>FOXP1</italic> mutations</title>
<p id="Par15">We searched the published literature for mutations in <italic>FOXP1</italic> using PubMed, the Human Gene Mutation Database (HGMD) Professional (Biobase), and denovo-db [<xref ref-type="bibr" rid="CR36">36</xref>]. We retrieved and examined the genetic information from all studies indicated in Additional file <xref ref-type="media" rid="MOESM2">2</xref>: Table S1. We also included pathogenic mutations reported in ClinVar (NCBI, <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/clinvar">http://www.ncbi.nlm.nih.gov/clinvar/</ext-link>). All mutations were annotated on NM_032682.5 and NP_116071.2.</p>
</sec>
<sec id="Sec6">
<title>Validation of the splice site mutation in individual S1</title>
<p id="Par16">Peripheral blood samples from individual S1 and her parents were collected in PAXgene® RNA tubes (Qiagen) and total RNA was extracted and purified using the PAXgene® Blood RNA kit, v2 (PreAnalytix). Globin mRNA was depleted from the samples using the GLOBINclear-Human Kit (Life Technologies). The quantity and quality of the purified RNA samples were measured on a Nanodrop. Total RNA (500 ng) was used for cDNA synthesis using SuperScript® II reverse transcriptase (Invitrogen). cDNA was amplified using exon-specific primers in exon 6 (SDR4345: 5′-GGACAGCTCTCAGTCCACAC-3′) and exon 9 (SDR4346: 5′-AGGTGGGTCATCATGGCTTG-3′). PCR products were extracted and purified from a 1% agarose gel using the QIAquick gel extraction kit (Qiagen) and subjected to Sanger sequencing with both forward and reverse primers (Genewiz).</p>
</sec>
<sec id="Sec7">
<title>Structural analyses</title>
<p id="Par17">The average three-dimensional structure of the FOXP1 DNA binding domain was extracted from PDB #2KIU, which contains 20 NMR structures [<xref ref-type="bibr" rid="CR37">37</xref>], and then superimposed to the FOXP2 domain co-crystallized with one double-stranded DNA molecule (PDB #2AO7) [<xref ref-type="bibr" rid="CR38">38</xref>]. We mapped all missense and in-frame mutations from this and prior studies on to this structure. Visual inspection of the FOXP1 domain structure and the three-dimensional superposition was performed using UCSF Chimera 1.10.1 [<xref ref-type="bibr" rid="CR39">39</xref>]. Figures were prepared using UCSF ChimeraX.</p>
</sec>
<sec id="Sec8">
<title>Clinical evaluation</title>
<p id="Par18">A detailed clinical evaluation was completed, including medical history, psychiatric and neurological evaluation, and dysmorphology examination by clinical geneticists. Medical records were also reviewed, including magnetic resonance imaging (MRI) and electroencephalogram (EEG).</p>
<sec id="Sec9">
<title>ASD symptomatology</title>
<p id="Par19">ASD diagnosis was determined using the Autism Diagnostic Observation Schedule, Second Edition (ADOS-2) [<xref ref-type="bibr" rid="CR40">40</xref>], the Autism Diagnostic Interview-Revised (ADI-R) [<xref ref-type="bibr" rid="CR41">41</xref>, <xref ref-type="bibr" rid="CR42">42</xref>], and a clinical evaluation with a child and adolescent psychiatrist or clinical psychologist. The ADOS-2 is a semi-structured direct assessment of social communication and restricted and repetitive behavior. The ADOS-2 produces a total score and domain scores in the areas of Social Affect and Restricted and Repetitive Behavior. Two clinically meaningful cut-offs can be obtained: <italic>autism spectrum</italic> and <italic>autism,</italic> the latter reflecting a greater number of symptoms. Symptom severity was assessed for both total score and individual domain scores [<xref ref-type="bibr" rid="CR43">43</xref>] using comparison scores ranging from 1 to 10. The ADI-R is a structured caregiver interview that assesses ASD symptoms in the areas of socialization, communication, and restricted and repetitive behavior. Caregiver questionnaires were completed to further assess everyday functioning and included the Social Responsiveness Scale, Second Edition [<xref ref-type="bibr" rid="CR44">44</xref>], the Repetitive Behavior Scale-Revised [<xref ref-type="bibr" rid="CR45">45</xref>, <xref ref-type="bibr" rid="CR46">46</xref>], and the Short Sensory Profile [<xref ref-type="bibr" rid="CR47">47</xref>]. A consensus diagnosis was determined for each individual based on ADOS-2, ADI-R, and clinical evaluation (DSM-5).</p>
</sec>
<sec id="Sec10">
<title>Intellectual and adaptive functioning</title>
<p id="Par20">Global cognitive ability was measured using the Stanford Binet Intelligence Scales, Fifth Edition (<italic>n</italic> = 5) [<xref ref-type="bibr" rid="CR48">48</xref>] and the Differential Ability Scales – Second Edition (<italic>n</italic> = 3) [<xref ref-type="bibr" rid="CR49">49</xref>]. Records from a Wechsler Preschool and Primary Scale of Intelligence – Third Edition [<xref ref-type="bibr" rid="CR50">50</xref>] was reviewed for one participant (W4). Full scale IQ (FSIQ), nonverbal IQ (NVIQ), and verbal IQ (VIQ) were obtained for 7/9 participants and ratio IQs were calculated for 2/9 participants (W1, W3). Adaptive behavior was measured using the Vineland Adaptive Behavior Scales, Second Edition, Survey Interview Form [<xref ref-type="bibr" rid="CR51">51</xref>]. The presence of ID was based on results from cognitive testing and the Vineland-II.</p>
</sec>
<sec id="Sec11">
<title>Expressive and receptive language</title>
<p id="Par21">Language milestones were assessed during the ADI-R and the clinical evaluation. Current expressive and receptive language abilities were measured using the Vineland-II (<italic>n</italic> = 9), the Peabody Picture Vocabulary Test, 4th Edition [<xref ref-type="bibr" rid="CR52">52</xref>] (<italic>n</italic> = 8), and the Expressive Vocabulary Test, 2nd Edition [<xref ref-type="bibr" rid="CR53">53</xref>] (<italic>n</italic> = 7).</p>
</sec>
<sec id="Sec12">
<title>Gross motor, fine motor, and visual-motor integration</title>
<p id="Par22">Motor milestones were assessed during the ADI-R and the clinical evaluation. Current fine and gross motor skills were measured using the Vineland-II (<italic>n</italic> = 5). Visual-motor integration was measured using the Developmental Test of Visual-Motor Integration, Sixth Edition [<xref ref-type="bibr" rid="CR54">54</xref>] (<italic>n</italic> = 7), which required individuals to copy shapes and patterns using pencil and paper. The Developmental Coordination Disorder Questionnaire [<xref ref-type="bibr" rid="CR55">55</xref>] was completed by all caregivers to measure motor control during movement, fine motor/handwriting skills, and general coordination. Scores below 57 are indicative of a developmental coordination disorder.</p>
</sec>
<sec id="Sec13">
<title>Psychiatric features</title>
<p id="Par23">The presence of internalizing and externalizing psychiatric symptoms was assessed during the psychiatric evaluation and through caregiver report forms including the Achenbach Child Behavior Checklist [<xref ref-type="bibr" rid="CR56">56</xref>] and the Aberrant Behavior Checklist [<xref ref-type="bibr" rid="CR57">57</xref>–<xref ref-type="bibr" rid="CR59">59</xref>].</p>
</sec>
</sec>
</sec>
<sec id="Sec14">
<title>Results</title>
<sec id="Sec15">
<title><italic>FOXP1</italic> mutational spectrum</title>
<p id="Par24">Our cohort consists of nine individuals with <italic>FOXP1</italic> mutations (Table <xref ref-type="table" rid="Tab1">1</xref>, Fig. <xref ref-type="fig" rid="Fig1">1</xref>) and one individual with a large duplication encompassing the <italic>FOXP1</italic> gene (Additional file <xref ref-type="media" rid="MOESM1">1</xref>). Three individuals had frameshift mutations introducing a premature stop codon, one individual had a nonsense mutation, one individual had a mutation in an essential splice site, three had missense mutations and one had an in-frame deletion (Table <xref ref-type="table" rid="Tab1">1</xref>, Fig. <xref ref-type="fig" rid="Fig1">1</xref>). The p.Tyr470Cys mutation is detected in a control in gnomAD and all other mutations are absent from EVS and gnomAD. Inheritance status is unknown for p.Leu414*, while all other mutations are confirmed de novo. All missense mutations are predicted to be damaging by Polyphen-2 and SIFT. Analysis of the <italic>FOXP1</italic> splicing in individual S1 reveals that the NM_032682.5:c.975-2A &gt; C in the acceptor splice site between exon 7 and 8 causes exon 8 skipping and results in a Lys325Asnfs*12 mutation (Fig. <xref ref-type="fig" rid="Fig2">2</xref>).<table-wrap id="Tab1"><label>Table 1</label><caption><p>
<italic>FOXP1</italic> mutations in this cohort</p></caption><table frame="hsides" rules="groups"><thead><tr><th>ID</th><th>Coding DNA change</th><th>Protein change</th><th>Genomic change</th><th>Effect</th><th>Inheritance</th></tr></thead><tbody><tr><td>S1</td><td>c.975-2A&gt;C</td><td>p.Lys325Asnfs*12</td><td>chr3:g.71050212T&gt;G</td><td>Splice-site</td><td>De novo</td></tr><tr><td>S2<sup>a</sup>
</td><td>c.1267_1268delGT</td><td>p.Val423Hisfs*37</td><td>chr3:g.71027059_71027060delAC</td><td>Frameshift</td><td>De novo</td></tr><tr><td>S3</td><td>c.1333_1335delinsAA</td><td>p.Val445Asnfs*29</td><td>chr3:g.71026992_71026994delinsTT</td><td>Frameshift</td><td>De novo</td></tr><tr><td>S4<sup>b</sup>
</td><td>c.1393A&gt;G</td><td>p.Arg465Gly</td><td>chr3:g.71026829T&gt;C</td><td>Missense</td><td>De novo</td></tr><tr><td>S5</td><td>c.1506C&gt;G</td><td>p.Phe502Leu</td><td>chr3:g.71026116G&gt;C</td><td>Missense</td><td>De novo</td></tr><tr><td>W1<sup>c</sup>
</td><td>c.1014dupA</td><td>p.Ala339Serfs*4</td><td>chr3:g.71050171dupT</td><td>Frameshift</td><td>De novo</td></tr><tr><td>W2</td><td>c.1240delC</td><td>p.Leu414*</td><td>chr3:g.71027087delG</td><td>Nonsense</td><td>Unknown</td></tr><tr><td>W3</td><td>c.1409A&gt;G</td><td>p.Tyr470Cys</td><td>chr3:g.71026813T&gt;C</td><td>Missense</td><td>De novo</td></tr><tr><td>W4</td><td>c.1590_1601delAGGGGCAGTATG</td><td>p.Gly531_Trp534del</td><td>chr3:g.71021757_71021768delCATACTGCCCCT</td><td>In-frame deletion</td><td>De novo</td></tr></tbody></table><table-wrap-foot><p>cDNA (NM_032682.5), protein (NP_116071.2/Q9H334–1), and genomic (GRCh37/hg19) changes are shown. Asterisks indicate stop codons</p><p>
<sup>a</sup>Individual S2 was previously reported by Lozano et al. (2015) [<xref ref-type="bibr" rid="CR4">4</xref>]</p><p>
<sup>b</sup>Individual S4 was previously reported by Sollis et al. (2016) (subject 1) [<xref ref-type="bibr" rid="CR5">5</xref>]</p><p>
<sup>c</sup>Individual W1 was previously reported by O’Roak et al. (2011) (subject 12817.p1) [<xref ref-type="bibr" rid="CR10">10</xref>], without clinical description</p></table-wrap-foot></table-wrap>
<fig id="Fig1"><label>Fig. 1</label><caption><p>
<italic>FOXP1</italic> mutations. The mutations described in this study and those described in the literature are shown in the upper and lower panels, respectively. FOXP1 domains are reported as described for Q9H334–1 in Uniprot. The two nuclear localization signals (NLS) are indicated as previously reported [<xref ref-type="bibr" rid="CR68">68</xref>]. Missense and in-frame mutations are indicated in blue, while loss-of-function (LoF) mutations are indicated in black. Recurrent mutations are indicated in bold. The position of c.975-2A &gt; C reflects the Lys325Asnfs*12 mutation. The positions of the other splice-site mutations reflect the first residue of the exon downstream of the intron</p></caption><graphic id="MO1" xlink:href="13229_2017_172_Fig1_HTML"></graphic></fig>
<fig id="Fig2"><label>Fig. 2</label><caption><p>Exon skipping caused by the c.975-2A &gt; C mutation. <bold>a</bold> RT-PCR results for exons 6–9 of <italic>FOXP1</italic> mRNA for blood-derived RNA for individual S1 and her parents. The upper band is the PCR amplicon resulting from the mRNA with exons 7 (blue), 8 (black), and 9 (purple); the lower band results from skipping of exon 8. <bold>b</bold> Sanger sequencing results of the PCR amplicons obtained in <bold>a</bold>. The nucleotide of the splice site mutated is indicated on the pre-mRNA in red</p></caption><graphic id="MO2" xlink:href="13229_2017_172_Fig2_HTML"></graphic></fig>
</p>
<p id="Par25">We searched through the published literature and ClinVar for pathogenic mutations in <italic>FOXP1</italic>. Besides the missense mutation with unknown inheritance reported in Worthey et al. (2013) [<xref ref-type="bibr" rid="CR9">9</xref>], all published mutations included in Additional file <xref ref-type="media" rid="MOESM2">2</xref>: Table S1 are confirmed as de novo. Notably, pathogenic missense or in-frame mutations in our cohort and in previous reports cluster to the DNA binding domain of FOXP1 (Figs. <xref ref-type="fig" rid="Fig1">1</xref> and <xref ref-type="fig" rid="Fig3">3</xref>), critical for the transcriptional activity of the protein. As shown for FOXP2, six copies of the FOX domains bind to two double-stranded segments of DNA, with two copies as monomers tightly associated with the DNA and four exhibiting domain swapping [<xref ref-type="bibr" rid="CR38">38</xref>]. In the monomers, the ~ 100 amino acids of the winged-helix DNA binding domain are arranged in five α-helices (H1-H5) and three β strands (β1-β3) (Fig. <xref ref-type="fig" rid="Fig3">3a</xref>) [<xref ref-type="bibr" rid="CR37">37</xref>, <xref ref-type="bibr" rid="CR38">38</xref>]. While H3, β2 and β3 are engaged in DNA recognition and binding, H2 and H4 are directly involved in the three-dimensional domain swapping (Fig. <xref ref-type="fig" rid="Fig3">3b</xref>).<fig id="Fig3"><label>Fig. 3</label><caption><p>Pathogenic missense mutations in the <italic>FOXP1</italic> DNA-binding domain. <bold>a</bold> Primary sequence and topological representation of the DNA-binding domain (as reported in PDB 2KIU). The five helices (H1-H5), the three β sheet (β1-β3) and the two wings regions (W1, W2) are shown. Residues mutated in the cohort described in this study are in red, while those affected by mutations described in literature are in blue. <bold>b</bold> Ribbon representation of the DNA binding domain of the FOXP1 monomer interacting with one double-stranded DNA molecule. The surface for the interaction with the DNA and the region involved in domain swapping are indicated by dashed lines. <bold>c</bold> Ribbon representation of the unbound FOXP1 DNA binding domain showing the missense mutations reported in the literature in blue (Additional file <xref ref-type="media" rid="MOESM2">2</xref>: Table S1). <bold>d</bold> Ribbon representation of the unbound FOXP1 DNA binding domain showing the missense and in-frame mutations reported in our cohort in red (Table <xref ref-type="table" rid="Tab1">1</xref>)</p></caption><graphic id="MO3" xlink:href="13229_2017_172_Fig3_HTML"></graphic></fig>
</p>
<p id="Par26">To understand the structural impact of the <italic>FOXP1</italic> mutations, we superimposed the structure of FOXP1 DNA binding domain [<xref ref-type="bibr" rid="CR37">37</xref>] on the structure of FOXP2 bound to the DNA [<xref ref-type="bibr" rid="CR38">38</xref>] and we mapped missense and in-frame mutations from this study and previous publications. Missense mutations previously reported (Fig. <xref ref-type="fig" rid="Fig3">3c</xref>) and identified in this cohort (Fig. <xref ref-type="fig" rid="Fig3">3d</xref>) disrupt amino acids located on both the DNA binding surface and on the helices involved in dimer formation through domain swapping. The Arg465 mutated in individual S4 is directly engaged in the DNA binding and the p.Arg465Gly mutation might affect the electrostatic interaction between the N-terminal region of the domain and the negatively charged backbone of the DNA (Fig. <xref ref-type="fig" rid="Fig3">3b, d</xref>). Similarly, the p.Gly531_Tpr534del in individual W4 removes four residues necessary for the three-stranded antiparallel β strands, likely compromising the folding of the domain and thus affecting DNA recognition. Within this region are also two previously reported mutations: p.Ala532Val [<xref ref-type="bibr" rid="CR15">15</xref>] and p.Trp534Arg [<xref ref-type="bibr" rid="CR13">13</xref>] (Fig. <xref ref-type="fig" rid="Fig3">3c</xref>). The Tyr470 residue mutated in W3 is part of an interaction network of aromatic residues located on H1, H3, H4 and H5 (Fig. <xref ref-type="fig" rid="Fig3">3d</xref>) and its mutation to Cys might result in the structural destabilization of the hydrophobic core of the protein. The Phe502 residue mutated in S5 is located on H4, which is involved in the domain swapping (Fig. <xref ref-type="fig" rid="Fig3">3d</xref>): reduction of steric hindrance in the core of the swapped dimer resulting from the p.Phe502Leu mutation might compromise FOXP1 dimerization.</p>
<p id="Par27">After removing cases ascertained or reported multiple times, we found seven instances of recurrent mutations (Fig. <xref ref-type="fig" rid="Fig1">1</xref>, Additional file <xref ref-type="media" rid="MOESM2">2</xref>: Table S1). The NM_032682.5:c.975-2A &gt; G mutation resulting in the Lys325Asnfs*12 mutation is detected in an individual in our cohort (S1, Fig. <xref ref-type="fig" rid="Fig2">2</xref>) and in an individual from an ID cohort screened by targeted sequencing [<xref ref-type="bibr" rid="CR11">11</xref>]. In addition, a mutation in the first nucleotide of the splice donor site (NM_032682.5:c.974 + 1G &gt; C) was found by WES in a DD/ID cohort [<xref ref-type="bibr" rid="CR12">12</xref>] (Fig. <xref ref-type="fig" rid="Fig1">1</xref>, Additional file <xref ref-type="media" rid="MOESM2">2</xref>: Table S1), but the consequences of this mutation on splicing have not been assessed. A p.Tyr439* mutation was reported in a Dutch individual included in Sollis et al. (2016) (individual 3) [<xref ref-type="bibr" rid="CR5">5</xref>] and independently identified in an individual screened by the Emory Genetics Laboratory at Emory University and deposited in ClinVar (#194566) (Fig. <xref ref-type="fig" rid="Fig1">1</xref>, Additional file <xref ref-type="media" rid="MOESM2">2</xref>: Table S1). Another nonsense mutation (p.Arg503*) was found in at least two independent cases reported in ClinVar (#211038). The mutation was also reported in a large-scale WES analysis [<xref ref-type="bibr" rid="CR14">14</xref>], but it is unclear whether this case overlaps with one of those in ClinVar. A third nonsense mutation (p.Arg525*) was reported in two independent cases [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR12">12</xref>] (Fig. <xref ref-type="fig" rid="Fig1">1</xref>, Additional file <xref ref-type="media" rid="MOESM2">2</xref>: Table S1). The other recurrent mutations are all missense mutations of residues located in the DNA binding domain (Pro466, Arg514, and Ala532) (Fig. <xref ref-type="fig" rid="Fig3">3a</xref>). Notably, the p.Pro466Leu is equivalent to the p.Pro505Leu in <italic>FOXP2</italic> that has been associated with language and speech impairment [<xref ref-type="bibr" rid="CR60">60</xref>]. Also, the p.Arg514His is equivalent to the <italic>FOXP2</italic> p.Arg553His mutation identified in childhood apraxia of speech [<xref ref-type="bibr" rid="CR26">26</xref>]. Arg514 and Arg553 in FOXP1 and FOXP2, respectively, are located in the DNA binding surface that intercalates with the major groove of the DNA (Fig. <xref ref-type="fig" rid="Fig3">3b</xref>, <xref ref-type="fig" rid="Fig3">c</xref>) and p.Arg553His has been shown to cause protein mislocalization, with the formation of nuclear and cytoplasmic aggregates, and abolish the binding to DNA and transactivation [<xref ref-type="bibr" rid="CR61">61</xref>].</p>
</sec>
<sec id="Sec16">
<title>Neuropsychological phenotype of FOXP1 syndrome</title>
<p id="Par28">An extensive battery of clinical assessments was employed to delineate the core phenotype of FOXP1 syndrome. To examine the neuropsychological phenotype, gold-standard assessment of ASD symptomatology, cognitive functioning, adaptive behavior, receptive and expressive language, fine and gross motor skills, and visual-motor integration was completed for participants S1-S6 and W1-W4 (Table <xref ref-type="table" rid="Tab2">2</xref>). Results for individual S6, who carries a large duplication spanning <italic>FOXP1</italic>, interpreted conservatively as of unknown significance (Additional file <xref ref-type="media" rid="MOESM1">1</xref>: Figure S1), are discussed in Additional file <xref ref-type="media" rid="MOESM1">1</xref>.<table-wrap id="Tab2"><label>Table 2</label><caption><p>Neuropsychological and psychiatric manifestations in individuals with FOXP1 syndrome</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Neuropsychological assessments</th><th>S1</th><th>S2</th><th>S3</th><th>S4</th><th>S5</th><th>W1</th><th>W2</th><th>W3</th><th>W4</th><th>Total(%)/Average</th></tr></thead><tbody><tr><td>Age (months)</td><td>71</td><td>200</td><td>133</td><td>138</td><td>96</td><td>191</td><td>134</td><td>118</td><td>117</td><td>133.1</td></tr><tr><td colspan="11">ASD symptoms</td></tr><tr><td> ASD on ADOS-2<sup>a</sup>
</td><td>–</td><td>+</td><td>++</td><td>–</td><td>–</td><td>++</td><td>–</td><td>++</td><td>n/a</td><td>4/8 (50%)</td></tr><tr><td> ADOS-2 Comparison Score</td><td>3</td><td>5</td><td>7</td><td>3</td><td>3</td><td>10</td><td>1</td><td>6</td><td>n/a</td><td>4.8</td></tr><tr><td> ASD on ADI-R</td><td>+</td><td>+</td><td>+</td><td>–</td><td>–</td><td>+</td><td>–</td><td>–</td><td>–</td><td>4/9 (44%)</td></tr><tr><td> Consensus diagnosis of ASD</td><td>–</td><td>–</td><td>–</td><td>–</td><td>–</td><td>+</td><td>–</td><td>+</td><td>n/a</td><td>2/8 (25%)</td></tr><tr><td colspan="11">Cognitive functioning (SS)</td></tr><tr><td> Nonverbal IQ</td><td>95</td><td>44</td><td>56</td><td>61</td><td>73</td><td>19</td><td>59</td><td>31</td><td>70</td><td>56.4</td></tr><tr><td> Verbal IQ</td><td>92</td><td>44</td><td>51</td><td>59</td><td>58</td><td>15</td><td>40</td><td>24</td><td>74</td><td>50.8</td></tr><tr><td> Full scale IQ</td><td>93</td><td>42</td><td>51</td><td>59</td><td>64</td><td>17</td><td>52</td><td>29</td><td>68</td><td>52.8</td></tr><tr><td colspan="11">Adaptive behavior (SS)</td></tr><tr><td> Vineland-II communication</td><td>81</td><td>59</td><td>69</td><td>67</td><td>74</td><td>42</td><td>61</td><td>57</td><td>67</td><td>64.1</td></tr><tr><td> Vineland-II daily Living</td><td>64</td><td>47</td><td>58</td><td>58</td><td>78</td><td>38</td><td>52</td><td>62</td><td>66</td><td>58.1</td></tr><tr><td> Vineland-II socialization</td><td>74</td><td>54</td><td>64</td><td>69</td><td>83</td><td>42</td><td>68</td><td>55</td><td>69</td><td>64.2</td></tr><tr><td> Vineland-II composite</td><td>69</td><td>53</td><td>62</td><td>63</td><td>77</td><td>39</td><td>59</td><td>59</td><td>67</td><td>60.9</td></tr><tr><td colspan="11">Language (AE in months)</td></tr><tr><td> Expressive vocabulary<sup>b</sup>
</td><td>55</td><td>78</td><td>94</td><td>95</td><td>59</td><td>n/a</td><td>81</td><td>35</td><td>n/a</td><td>71.0</td></tr><tr><td> Receptive vocabulary<sup>c</sup>
</td><td>56</td><td>69</td><td>75</td><td>93</td><td>54</td><td>44</td><td>81</td><td>29</td><td>n/a</td><td>62.6</td></tr><tr><td> Vineland-II expressive</td><td>42</td><td>48</td><td>59</td><td>54</td><td>55</td><td>25</td><td>52</td><td>23</td><td>46</td><td>44.9</td></tr><tr><td> Vineland-II receptive</td><td>41</td><td>35</td><td>47</td><td>47</td><td>30</td><td>34</td><td>26</td><td>34</td><td>30</td><td>36.0</td></tr><tr><td colspan="11">Motor skills</td></tr><tr><td> Visual-motor integration (SS)<sup>d</sup>
</td><td>78</td><td>45</td><td>&lt;45</td><td>45</td><td>70</td><td>n/a</td><td>47</td><td>&lt;45</td><td>n/a</td><td>&lt; 53.6</td></tr><tr><td> Vineland-II gross motor (AE)</td><td>46</td><td>n/a</td><td>47</td><td>82</td><td>59</td><td>n/a</td><td>n/a</td><td>37</td><td>n/a</td><td>54.2</td></tr><tr><td> Vineland-II fine motor (AE)</td><td>34</td><td>n/a</td><td>69</td><td>66</td><td>68</td><td>n/a</td><td>n/a</td><td>36</td><td>n/a</td><td>54.6</td></tr><tr><td colspan="11">Psychiatric features</td></tr><tr><td> Anxiety</td><td>+</td><td>+</td><td>+</td><td>+</td><td>+</td><td>+</td><td>+</td><td>–</td><td>+</td><td>8/9 (89%)</td></tr><tr><td> Compulsive behaviors</td><td>+</td><td>+</td><td>+</td><td>+</td><td>+</td><td>+</td><td>+</td><td>+</td><td>+</td><td>9/9 (100%)</td></tr><tr><td> Attention problems</td><td>+</td><td>+</td><td>+</td><td>+</td><td>+</td><td>+</td><td>+</td><td>+</td><td>+</td><td>9/9 (100%)</td></tr><tr><td> Externalizing symptoms</td><td>+</td><td>+</td><td>+</td><td>+</td><td>+</td><td>+</td><td>+</td><td>+</td><td>+</td><td>9/9 (100%)</td></tr></tbody></table><table-wrap-foot><p>
<sup>a</sup>ADOS-2 classification: + = autism spectrum; ++ = autism</p><p>
<sup>b</sup>Expressive vocabulary measured by the Expressive Vocabulary Test, 2nd Edition</p><p>
<sup>c</sup>Receptive vocabulary measured by the Peabody Picture Vocabulary Test, 4th Edition</p><p>
<sup>d</sup>Visual-motor integration measured by the Test of Visual-Motor Integration, 6th Edition</p><p>
<italic>ADI-R</italic> Autism Diagnostic Interview-Revised, <italic>ADOS-2</italic> Autism Diagnostic Observation Schedule, 2nd Edition, <italic>AE</italic> age equivalents, <italic>SS</italic> standard score, <italic>n/a</italic> information not available</p></table-wrap-foot></table-wrap>
</p>
<p id="Par29">
<italic>ASD symptoms.</italic> Participants S1-S5 and W1-W3 received ASD diagnostic testing and a clinical evaluation to assess DSM-5 criteria for ASD (Additional file <xref ref-type="media" rid="MOESM3">3</xref>: Table S2). All individuals displayed ASD symptoms, however only two of the eight individuals evaluated for ASD (W1 and W3) received a diagnosis of ASD (25%) based on expert clinical consensus.</p>
<p id="Par30">Four individuals (S1–3, W2) were administered a Module 3 of the ADOS-2 (indicating the presence of fluent speech), two individuals (S4–5) were administered a Module 2 (indicating the presence of phrase speech), and two individuals (W1, W3) received a Module 1 (indicating use of single words or no words). Four of eight individuals met criteria on the ADOS-2; three individuals (S3, W1, W3) were above the cutoff for an <italic>autism</italic> classification and one (S2) was above the cutoff for an <italic>autism spectrum</italic> classification. The two individuals who met criteria for a <italic>clinical diagnosis</italic> of ASD received a Module 1 of the ADOS-2, suggesting limited language ability. ADOS-2 overall comparison scores ranged from 1 to 10 (4.8 ± 2.9). Comparison scores for individual ADOS-2 domains indicated higher scores in the Restricted and Repetitive Behavior domain (6 ± 2.7) as compared to the Social Affect domain (4.8 ± 1.8<italic>)</italic>.</p>
<p id="Par31">On the ADI-R (<italic>n</italic> = 9), four individuals were above the cutoff for ASD on all domains, six were above the cutoff on the Social domain and seven were above the cutoff on the Communication and Restricted and Repetitive Behavior domains.</p>
<p id="Par32">ASD symptoms were further assessed through caregiver report questionnaires. Results from the Social Responsiveness Scale, 2nd Edition (<italic>n</italic> = 9) indicated deficits across all domains (76.4 ± 7.8). Social motivation fell within the mild range of impairment (65.2 ± 8.3) as compared to moderate impairment in social communication (74.8 ± 9.10), social awareness (74.9 ± 6.6), and repetitive behavior (75.6 ± 8.6), and severe impairment in social cognition (76.8 ± 9.5).</p>
<p id="Par33">In the area of repetitive behavior and restricted interests, scores on the Repetitive Behavior Scale-Revised (<italic>n</italic> = 9) were all within one standard deviation of norms published in individuals with ASD [<xref ref-type="bibr" rid="CR62">62</xref>]. Within this cohort, the greatest number of symptoms was reported for insistence on sameness (5.6 ± 2.7, range: 2–10). Average self-injurious behaviors scores were higher than the reference sample (4.6 ± 4.0), however scores varied across participants (range: 0–13). On the Short Sensory Profile (<italic>n</italic> = 5), total scores indicated definite sensory differences in three individuals, possible differences in one individual, and typical performance in one individual. An examination of individual domains indicates the greatest number of symptoms in the area of underresponsive/seeks sensation with four of five individuals (S1, S3–4) meeting criteria for a definite sensory difference in this domain.</p>
<p id="Par34">Results from the psychiatric evaluation provided additional detail on restricted and repetitive behavior in individuals with FOXP1 syndrome. Common repetitive behaviors included intense and highly restrictive interests, stereotypic movements such as hand flapping, insistence on sameness, or adherence to routines. Caregivers also reported compulsive behaviors in all individuals, which included hoarding of small objects. Of note, five out of the nine (56%) participants were reported to engage in compulsive picking of the skin and nails.</p>
<sec id="Sec17">
<title>Intellectual and adaptive functioning</title>
<p id="Par35">Five individuals received the Stanford-Binet, 5th Edition (S1-S5), three individuals received the Differential Ability Scales, 2nd Edition (W1-W3), and one individual received the Wechsler Preschool and Primary Scale of Intelligence – Third Edition (W4; record review). Developmental quotients based on ratio IQs were calculated for the Differential Ability Scales as the test was administered out of the normed age range. Standard scores across the seven individuals for which deviation IQs could be calculated ranged from 42 to 93 (62.7 ± 16.5) for FSIQ, 44 to 95 (66.3 ± 16.1) for NVIQ, and 40 to 92 (61.1 ± 18.1) for VIQ. Nonverbal developmental quotients (DQ) for individuals W1 and W3 were 19 and 31, respectively, and verbal DQs were 15 and 24, respectively. Overall, results indicate a range of cognitive ability across individuals, although NVIQ and VIQ were evenly developed within individual profiles.</p>
<p id="Par36">Results from the Vineland-II indicate that overall adaptive functioning was consistent with cognitive functioning. Standard scores on the adaptive behavior composite ranged from 39 to 77 (60.9 ± 10.7). Mean scores were comparable across domains of communication (64.1 ± 11.2), daily living skills (58.1 ± 11.6), and socialization (64.2 ± 12.2).</p>
<p id="Par37">Overall, seven of nine individuals (78%) received a clinical diagnosis of ID, one displayed borderline intellectual functioning (S5) and one fell in the average range (S1). It is notable that S1 is the youngest participant in the sample and her cognitive functioning was significantly better developed than her adaptive functioning. This is remarkable in light of the fact that she carries an early truncating mutation (Figs. <xref ref-type="fig" rid="Fig1">1</xref> and <xref ref-type="fig" rid="Fig2">2</xref>).</p>
</sec>
<sec id="Sec18">
<title>Expressive and receptive language</title>
<p id="Par38">Early language milestones were delayed in eight of nine individuals. First single words emerged between 14 and 42 months (26.8 ± 11.7), and first phrases emerged between 24 and 96 months (53 ± 23.1). Current expressive and receptive language abilities were assessed using norm-referenced measures including the Expressive Vocabulary Test, 2nd Edition (<italic>n</italic> = 7) and Peabody Picture Vocabulary Test, 4th Edition (<italic>n</italic> = 8). Results indicated stronger expressive language skills (69.4 ± 17.5) as compared to receptive language skills (55.8 ± 25.9). Expressive language standard scores ranged from 35 to 86 and receptive language scores ranged from 20 to 85. An analysis of individual results indicates that expressive language standard scores were higher than receptive language scores for all participants. Language abilities were also measured through caregiver interview via the Vineland-II (<italic>n</italic> = 9). Overall standard scores in the Communication domain ranged from 42 to 81 (64.1 ± 11.2). Age equivalents (AE) for all language measures are presented in Table <xref ref-type="table" rid="Tab2">2</xref>.</p>
</sec>
<sec id="Sec19">
<title>Gross motor, fine motor and visual-motor integration</title>
<p id="Par39">All individuals were delayed in achieving motor milestones. First crawling (<italic>n</italic> = 6) was reported between 12 and 18 months (14.8 ± 2.5) and first walking unaided (<italic>n</italic> = 9) was reported between 18 and 33 months (22.3 ± 4.4). Standard scores on the Developmental Test of Visual-Motor Integration (<italic>n</italic> = 7) ranged from &lt; 45 to 78 (53.6 ± 14.2). Five individuals scored in the impaired range (Standard score (SS) &lt; 50) and two individuals fell in the borderline range (SS = 70 and 78). Results from the Developmental Coordination Disorder Questionnaire (<italic>n</italic> = 8) provided further evidence of developmental coordination difficulties in all individuals (26.3 ± 6.6, range 15–35). Difficulties were reported across all three domains. Five individuals were administered the Vineland-II motor domain. Standard scores ranged from 61 to 91 (76.6 ± 11.1) with gross motor skills (54.2 ± 17.4) and fine motor skills (54.6 ± 17.9) reported as similarly developed.</p>
</sec>
<sec id="Sec20">
<title>Psychiatric features</title>
<p id="Par40">Results from the Aberrant Behavior Checklist (<italic>n</italic> = 6) indicated elevated scores on the hyperactivity/noncompliance (62 ± 3.1, range: 57–66) and irritability/agitation (60.3 ± 3.5, range: 57–66) subscales. Scores were within normal limits on the lethargy/social withdrawal, stereotypic behavior and inappropriate speech subscales. Results from the empirically based scales of the Child Behavior Checklist (<italic>n</italic> = 6) indicated clinically significant levels of Attention Deficit/Hyperactivity Disorder (ADHD) symptoms, oppositional defiant problems, and conduct problems (<italic>t</italic> scores &gt; 70). Anxiety problems, including obsessive-compulsive symptoms, fell in the elevated range (1.5 SD above the mean).</p>
<p id="Par41">Results from the psychiatric evaluation revealed ADHD symptoms of inattention, hyperactivity and impulsivity in all nine individuals, with different degrees of severity and impairment. Aggression (7/9, 78%), irritability (8/9, 89%), mood lability (8/9, 89%) and self-injurious behaviors (5/9, 56%) were also present in most participants causing significant impact on daily activities. All individuals presented with anxiety symptoms in some form. Sleep problems were present in four of the nine participants (44%), and were mostly characterized by difficulty initiating sleep and multiple awakenings throughout the night. Results are summarized in Table <xref ref-type="table" rid="Tab2">2</xref>.</p>
</sec>
</sec>
<sec id="Sec21">
<title>Other medical features of the FOXP1 syndrome</title>
<p id="Par42">In addition to the neuropsychological evaluation, a multidisciplinary team of clinicians carried out psychiatric, medical, neurological, and dysmorphology examinations.</p>
<sec id="Sec22">
<title>Medical features</title>
<p id="Par43">Only two individuals in our cohort were found to have a congenital heart defect and/or electrocardiogram abnormalities (Table <xref ref-type="table" rid="Tab3">3</xref>). Sinopulmonary infections were common, with recurrent otitis media reported in six out of nine (67%) individuals and recurrent upper respiratory tract infection present in four out of nine (44%) individuals. Recurrent skin infections were noted in two out of nine individuals (22%). One individual (11%) had a significant history of pulmonary problems characterized by neuroendocrine hyperplasia of infancy and pulmonary hypertension; this individual required 24-h oxygen therapy for the first 3 years of life, followed by nighttime oxygen until age five. Five out of nine (56%) individuals had visual refractive errors and strabismus.<table-wrap id="Tab3"><label>Table 3</label><caption><p>Medical findings in individuals with FOXP1 syndrome</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Medical feature</th><th>S1</th><th>S2</th><th>S3</th><th>S4</th><th>S5</th><th>W1</th><th>W2</th><th>W3</th><th>W4</th><th>Total (%)</th></tr></thead><tbody><tr><td colspan="11">Cardiac</td></tr><tr><td> Congenital heart defect</td><td>–</td><td>–</td><td>–</td><td>–</td><td>+<sup>a</sup>
</td><td>–</td><td>–</td><td>–</td><td>+<sup>b</sup>
</td><td>2/9 (22%)</td></tr><tr><td> Abnormal electrocardiogram</td><td>–</td><td>n/a</td><td>n/a</td><td>n/a</td><td>+</td><td>n/a</td><td>n/a</td><td>n/a</td><td>n/a</td><td>1/2 (50%)</td></tr><tr><td colspan="11">Sinopulmonary</td></tr><tr><td> Recurrent otitis media</td><td>–</td><td>–</td><td>+</td><td>+</td><td>+</td><td>+</td><td>–</td><td>+</td><td>+</td><td>6/9 (67%)</td></tr><tr><td> Recurrent upper respiratory tract infections</td><td>–</td><td>–</td><td>+</td><td>–</td><td>–</td><td>+</td><td>–</td><td>+</td><td>+</td><td>4/9 (44%)</td></tr><tr><td> Neuroendocrine hyperplasia of infancy</td><td>+</td><td>–</td><td>–</td><td>–</td><td>–</td><td>–</td><td>–</td><td>–</td><td>–</td><td>1/9 (11%)</td></tr><tr><td> Pulmonary hypertension</td><td>+</td><td>–</td><td>–</td><td>–</td><td>–</td><td>–</td><td>–</td><td>–</td><td>–</td><td>1/9 (11%)</td></tr><tr><td colspan="11">Urinary tract</td></tr><tr><td> Genitourinary abnormalities</td><td>–</td><td>–</td><td>+</td><td>n/a</td><td>–</td><td>–</td><td>–</td><td>–</td><td>–</td><td>1/8 (13%)</td></tr><tr><td colspan="11">Endocrine</td></tr><tr><td> Body mass index (percentile for age)</td><td>27.8</td><td>85.8</td><td>69.8</td><td>82.1</td><td>58.7</td><td>20.2</td><td>15.4</td><td>19.7</td><td>n/a</td><td></td></tr><tr><td> Overweight</td><td>–</td><td>+</td><td>–</td><td>–</td><td>–</td><td>–</td><td>–</td><td>–</td><td>n/a</td><td>1/8 (13%)</td></tr><tr><td> Hypothyroidism</td><td>–</td><td>–</td><td>–</td><td>–</td><td>–</td><td>+</td><td>–</td><td>–</td><td>–</td><td>1/9 (11%)</td></tr><tr><td> Diabetes mellitus</td><td>–</td><td>–</td><td>–</td><td>–</td><td>–</td><td>+</td><td>–</td><td>–</td><td>–</td><td>1/9 (11%)</td></tr><tr><td colspan="11">Other medical</td></tr><tr><td> Constipation</td><td>+</td><td>+</td><td>–</td><td>–</td><td>–</td><td>–</td><td>–</td><td>+</td><td>+</td><td>4/9 (44%)</td></tr><tr><td> Skin infections</td><td>–</td><td>–</td><td>–</td><td>+</td><td>–</td><td>–</td><td>–</td><td>–</td><td>+</td><td>2/9 (22%)</td></tr><tr><td> Allergies</td><td>–</td><td>+</td><td>–</td><td>–</td><td>–</td><td>+</td><td>–</td><td>–</td><td>–</td><td>2/9 (22%)</td></tr><tr><td> Iron deficiency</td><td>–</td><td>–</td><td>–</td><td>–</td><td>–</td><td>+</td><td>–</td><td>–</td><td>+</td><td>2/9 (22%)</td></tr><tr><td> Visual refractive error</td><td>–</td><td>+</td><td>+</td><td>–</td><td>+</td><td>–</td><td>+</td><td>–</td><td>+</td><td>5/9 (56%)</td></tr><tr><td> Strabismus</td><td>–</td><td>+</td><td>+</td><td>–</td><td>+</td><td>–</td><td>+</td><td>–</td><td>+</td><td>5/9 (56%)</td></tr></tbody></table><table-wrap-foot><p>
<sup>a</sup>Pulmonary valve stenosis</p><p>
<sup>b</sup>Patent ductus arteriosus discovered at 14 months that resolved without intervention</p><p>
<italic>n/a</italic> information not available</p></table-wrap-foot></table-wrap>
</p>
<p id="Par44">Endocrine problems were fairly common in our cohort, with two out of eight (25%) individuals falling below the 3rd percentile for stature, and two out of eight (25%) above the 80th percentile for age-expected body mass index. One child had hypothyroidism and type II diabetes mellitus. Constipation affected four out of nine individuals (44%). Two out of nine individuals (22%) had iron deficiency anemia, which was associated with restless leg syndrome in one of them. One individual (S3) showed a duplicated left-sided renal collecting duct system that required surgical repair. Genitourinary abnormalities were not reported in any other cases in this cohort.</p>
</sec>
<sec id="Sec23">
<title>Neurological features</title>
<p id="Par45">All individuals who underwent neurological examination were found to present with fine and gross motor coordination deficits and dysarthria (Table <xref ref-type="table" rid="Tab4">4</xref>). Hypotonia (89%), and mild gait abnormalities (78%) were also present in the majority of individuals. Early feeding issues, such as sucking and swallowing, were present in one third of our sample. Individual S3 presented with a tethered cord diagnosed shortly after birth. All individuals had difficulty attaining bladder control, with enuresis present in three out of nine (33%) participants. Results from brain MRIs were available for seven out of the nine participants, with abnormal findings identified in six (86%) of them (Table <xref ref-type="table" rid="Tab4">4</xref>) (including S4 [<xref ref-type="bibr" rid="CR5">5</xref>] previously reported). The most common finding was enlarged ventricles (<italic>n</italic> = 3). In addition, we observed cases with a small partial cavum septum pellucidum (<italic>n</italic> = 1), mild diffuse periventricular leukomalacia (<italic>n</italic> = 1), and arachnoid cysts in the left hemisphere and cerebellum (<italic>n</italic> = 1). Two of our participants had abnormal EEG findings in the absence of clinical seizures. There was no report of signs suggestive of a seizure disorder in any individual.<table-wrap id="Tab4"><label>Table 4</label><caption><p>Neurological findings in individuals with FOXP1 syndrome</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Neurological feature</th><th>S1</th><th>S2</th><th>S3</th><th>S4</th><th>S5</th><th>W1</th><th>W2</th><th>W3</th><th>W4</th><th>Total (%)</th></tr></thead><tbody><tr><td>Brain imaging abnormality</td><td>+ <sup>a</sup>
</td><td>+ <sup>b</sup>
</td><td>+ <sup>c</sup>
</td><td>+ <sup>d</sup>
</td><td>n/a</td><td>–</td><td>n/a</td><td>+ <sup>e</sup>
</td><td>+ <sup>f</sup>
</td><td>6/7 (86%)</td></tr><tr><td>EEG abnormality</td><td>n/a</td><td>n/a</td><td>–</td><td>n/a</td><td>n/a</td><td>+</td><td>n/a</td><td>–</td><td>+</td><td>2/4 (50%)</td></tr><tr><td>Hypotonia</td><td>+</td><td>+</td><td>+</td><td>+</td><td>+</td><td>–</td><td>+</td><td>+</td><td>+</td><td>8/9 (89%)</td></tr><tr><td>Feeding issues (past/present)</td><td>+</td><td>–</td><td>–</td><td>–</td><td>+</td><td>–</td><td>–</td><td>+</td><td>–</td><td>3/9 (33%)</td></tr><tr><td>Dysarthria</td><td>+</td><td>+</td><td>+</td><td>+</td><td>+</td><td>+</td><td>+</td><td>+</td><td>+</td><td>9/9 (100%)</td></tr><tr><td>Gait abnormalities</td><td>+</td><td>+</td><td>+</td><td>+</td><td>+</td><td>+</td><td>–</td><td>+</td><td>–</td><td>7/9 (78%)</td></tr><tr><td>Fine/gross motor coordination deficit</td><td>+</td><td>+</td><td>+</td><td>+</td><td>+</td><td>+</td><td>+</td><td>+</td><td>+</td><td>9/9 (100%)</td></tr><tr><td>Hypoacusis/hearing loss</td><td>–</td><td>–</td><td>–</td><td>–</td><td>–</td><td>–</td><td>–</td><td>–</td><td>+</td><td>1/9 (11%)</td></tr><tr><td>Spinal cord malformation</td><td>–</td><td>–</td><td>+<sup>g</sup>
</td><td>–</td><td>–</td><td>–</td><td>–</td><td>–</td><td>–</td><td>1/9 (11%)</td></tr></tbody></table><table-wrap-foot><p>
<sup>a</sup>Mildly dilated lateral ventricles</p><p>
<sup>b</sup>Non-enhancing subcortical and deep white matter abnormalities; incidental finding of venous angioma in left frontal lobe</p><p>
<sup>c</sup>Prominent Virchow-Robin spaces. Small partial cavum septum pellucidum anteriorly</p><p>
<sup>d</sup>Mild diffuse periventricular leukomalacia</p><p>
<sup>e</sup>Arachnoid cysts (cerebellum, left hemisphere); enlarged ventricles</p><p>
<sup>f</sup>Enlarged ventricles</p><p>
<sup>g</sup>Tethered cord and conus medullaris terminating at the lumbar spine segment L3</p><p>
<italic>n/a</italic> information not available</p></table-wrap-foot></table-wrap>
</p>
</sec>
<sec id="Sec24">
<title>Dysmorphic features</title>
<p id="Par46">Comprehensive dysmorphology examination was performed in eight out of nine participants (Table <xref ref-type="table" rid="Tab5">5</xref>). All participants had a least three dysmorphic features (range 3–13, 7.9 ± 3.6), which is relatively consistent to previous reports. None of the identified dysmorphic features were specific to this syndrome. The most common features observed were broad nasal bridge (75%), prominent forehead (75%), bulbous nose (63%), high arched palate (50%), clinodactyly (50%), macrocephaly (50%), and hypertelorism (50%) (Fig. <xref ref-type="fig" rid="Fig4">4</xref> and Table <xref ref-type="table" rid="Tab5">5</xref>).<table-wrap id="Tab5"><label>Table 5</label><caption><p>Dysmorphisms in individuals with FOXP1 syndrome</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Dysmorphisms</th><th>S1</th><th>S2</th><th>S3</th><th>S4</th><th>S5</th><th>W1</th><th>W2</th><th>W3</th><th>W4</th><th>Total (%)</th></tr></thead><tbody><tr><td>Height in cm (percentile)<break></break>Short Stature</td><td>112 (35.9)<break></break>−</td><td>160.5 (35.6)<break></break>−</td><td>146 (57.4)<break></break>−</td><td>132.5 (2.6)<break></break>+</td><td>124 (27.7)<break></break>−</td><td>165.4 (24.4)<break></break>−</td><td>131 (2.4)<break></break>+</td><td>130 (14)<break></break>−</td><td>n/a</td><td>2/8 (25%)</td></tr><tr><td>Macrocephaly (percentile)</td><td>−(97)</td><td>+(&gt; 99)</td><td>−(75)</td><td>+(&gt; 99)</td><td>+(&gt; 99)</td><td>−(83)</td><td>−(63)</td><td>+(&gt; 99)</td><td>n/a</td><td>4/8 (50%)</td></tr><tr><td>Broad nasal bridge</td><td>+</td><td>+</td><td>+</td><td>+</td><td>+</td><td>–</td><td>+</td><td>–</td><td>n/a</td><td>6/8 (75%)</td></tr><tr><td>Prominent forehead</td><td>+</td><td>+</td><td>–</td><td>+</td><td>+</td><td>–</td><td>+</td><td>+</td><td>n/a</td><td>6/8 (75%)</td></tr><tr><td>Bulbous nose</td><td>+</td><td>+</td><td>+</td><td>+</td><td>+</td><td>–</td><td>–</td><td>–</td><td>n/a</td><td>5/8 (63%)</td></tr><tr><td>High arched palate</td><td>+</td><td>+</td><td>+</td><td>–</td><td>+</td><td>–</td><td>–</td><td>–</td><td>n/a</td><td>4/8 (50%)</td></tr><tr><td>Hypertelorism</td><td>–</td><td>+</td><td>–</td><td>+</td><td>+</td><td>–</td><td>+</td><td>–</td><td>n/a</td><td>4/8 (50%)</td></tr><tr><td>Clinodactyly</td><td>–</td><td>–</td><td>–</td><td>+</td><td>+</td><td>+</td><td>–</td><td>+</td><td>n/a</td><td>4/8 (50%)</td></tr><tr><td>Epicanthal folds</td><td>–</td><td>–</td><td>–</td><td>+</td><td>–</td><td>+</td><td>+</td><td>–</td><td>n/a</td><td>3/8 (38%)</td></tr><tr><td>Malocclusion</td><td>+</td><td>+</td><td>–</td><td>+</td><td>–</td><td>–</td><td>–</td><td>–</td><td>n/a</td><td>3/8 (38%)</td></tr><tr><td>Long philtrum</td><td>–</td><td>+</td><td>+</td><td>–</td><td>+</td><td>–</td><td>–</td><td>–</td><td>n/a</td><td>3/8 (38%)</td></tr><tr><td>Thick vermillion</td><td>–</td><td>+</td><td>+</td><td>+</td><td>–</td><td>–</td><td>–</td><td>–</td><td>n/a</td><td>3/8 (38%)</td></tr><tr><td>Single palmar crease</td><td>+</td><td>–</td><td>–</td><td>–</td><td>–</td><td>+</td><td>–</td><td>–</td><td>n/a</td><td>2/8 (25%)</td></tr><tr><td>Pectus excavatum</td><td>+</td><td>–</td><td>+</td><td>–</td><td>–</td><td>–</td><td>–</td><td>–</td><td>n/a</td><td>2/8 (25%)</td></tr><tr><td>Frontal hair upsweep</td><td>+</td><td>–</td><td>–</td><td>–</td><td>–</td><td>–</td><td>–</td><td>+</td><td>n/a</td><td>2/8 (25%)</td></tr><tr><td>Ptosis</td><td>–</td><td>+</td><td>–</td><td>–</td><td>–</td><td>–</td><td>–</td><td>–</td><td>n/a</td><td>1/8 (13%)</td></tr><tr><td>Pointed chin</td><td>–</td><td>–</td><td>–</td><td>–</td><td>+</td><td>–</td><td>–</td><td>–</td><td>n/a</td><td>1/8 (13%)</td></tr><tr><td>Bicuspid uvula</td><td>–</td><td>–</td><td>–</td><td>–</td><td>+</td><td>–</td><td>–</td><td>–</td><td>n/a</td><td>1/8 (13%)</td></tr><tr><td>Partial syndactyly 2nd and 3rd toes</td><td>+</td><td>–</td><td>–</td><td>–</td><td>–</td><td>–</td><td>–</td><td>–</td><td>n/a</td><td>1/8 (13%)</td></tr><tr><td>Deep set eyes</td><td>+</td><td>–</td><td>–</td><td>–</td><td>–</td><td>–</td><td>–</td><td>–</td><td>n/a</td><td>1/8 (13%)</td></tr><tr><td>Scoliosis</td><td>–</td><td>–</td><td>–</td><td>+</td><td>–</td><td>–</td><td>–</td><td>–</td><td>n/a</td><td>1/8 (13%)</td></tr><tr><td>Short neck</td><td>–</td><td>–</td><td>–</td><td>+</td><td>–</td><td>–</td><td>–</td><td>–</td><td>n/a</td><td>1/8 (13%)</td></tr><tr><td>Sacral dimple</td><td>–</td><td>–</td><td>+</td><td>–</td><td>–</td><td>–</td><td>–</td><td>–</td><td>n/a</td><td>1/8 (13%)</td></tr><tr><td>Hyperflexibility</td><td>+</td><td>–</td><td>–</td><td>–</td><td>–</td><td>–</td><td>–</td><td>–</td><td>n/a</td><td>1/8 (13%)</td></tr><tr><td>Long eyelashes</td><td>–</td><td>–</td><td>–</td><td>+</td><td>–</td><td>–</td><td>–</td><td>–</td><td>n/a</td><td>1/8 (13%)</td></tr><tr><td>Total number of dysmorphic features</td><td>11</td><td>10</td><td>7</td><td>13</td><td>10</td><td>3</td><td>5</td><td>4</td><td>n/a</td><td>7.9 ± 3.6</td></tr></tbody></table><table-wrap-foot><p>
<italic>n/a</italic> information not available</p></table-wrap-foot></table-wrap>
<fig id="Fig4"><label>Fig. 4</label><caption><p>Dysmorphisms in individuals with <italic>FOXP1</italic> mutations. Most common features include prominent forehead (evident in <bold>a</bold>, <bold>b</bold>, <bold>c</bold>, <bold>d</bold>, <bold>g</bold>, and <bold>h</bold>), bulbous nose (evident in <bold>a</bold>, <bold>c</bold>, <bold>e</bold>, <bold>f</bold>, <bold>g,</bold> and <bold>h</bold>), broad nasal bridge (evident in <bold>a</bold>, <bold>b</bold>, <bold>c</bold>, <bold>e</bold>, and <bold>h</bold>), hypertelorism (evident in <bold>a</bold>, <bold>c,</bold> and <bold>h</bold>), thick vermillion (evident in <bold>e</bold>, <bold>f,</bold> and <bold>h</bold>), and long philtrum (evident in <bold>c</bold> and <bold>g</bold>)</p></caption><graphic id="MO4" xlink:href="13229_2017_172_Fig4_HTML"></graphic></fig>
</p>
</sec>
</sec>
</sec>
<sec id="Sec25">
<title>Discussion</title>
<p id="Par47">In this study, we report on the genetic and clinical spectrum of FOXP1 syndrome in a cohort of nine individuals with mutations in <italic>FOXP1</italic> and one individual with a large duplication spanning <italic>FOXP1,</italic> evaluated as of unknown significance.</p>
<p id="Par48">Few individuals have been described in the literature, but screening the emerging <italic>FOXP1</italic> mutational landscape reveals 34 private mutations and another 7 that recur in unrelated individuals and appear as mutation hotspots in the gene (Fig. <xref ref-type="fig" rid="Fig1">1</xref>). The identification of recurrent mutations has important implications for clinical genetics practice and offers the opportunity to evaluate clinical variability in FOXP1 syndrome. For example, individual S1 has average cognitive functioning, although she carries a mutation as disruptive as other loss-of-function mutations in our cohort (Fig. <xref ref-type="fig" rid="Fig2">2</xref>).</p>
<p id="Par49">Another key observation emerging from our analyses is that over 80% of the pathogenic missense mutations, including all four missense mutations in our cohort, lie in the DNA-binding domain and perturb amino acids that are necessary for the binding to the DNA or to the domain swapping that mediates FOXP1 dimerization (Fig. <xref ref-type="fig" rid="Fig3">3</xref>). This finding emphasizes the importance of carefully evaluating <italic>FOXP1</italic> missense variants and taking into account structural information when evaluating pathogenicity.</p>
<p id="Par50">Our clinical observations delineate a clinical spectrum of FOXP1 syndrome that includes a set of core phenotypic features, including delays in early motor and language milestones, language impairment, ASD symptoms (although subthreshold for a DSM-5 diagnosis in the majority of individuals), and visual-motor integration deficits (Table <xref ref-type="table" rid="Tab2">2</xref>). Psychiatric features were also prominent including anxiety, obsessive-compulsive traits, attention deficits, and externalizing symptoms. Cognitive ability ranged from profound ID to average, with the majority of individuals performing in the range of mild ID (standard scores between 50 and 70). Interestingly, there was not a significant difference between verbal and nonverbal abilities. Adaptive functioning was similarly developed, suggesting evenly developed skills.</p>
<p id="Par51">With regard to ASD symptoms, the majority of individuals fell above ASD cutoffs on standardized diagnostic assessments (ADOS-2, ADI-R); however, only two individuals met DSM-5 criteria for ASD (Additional file <xref ref-type="media" rid="MOESM3">3</xref>: Table S2). It is notable that a greater number of symptoms were observed in the Restricted and Repetitive Behavior domain as compared to the Social Communication domain. While results highlight the role of clinical judgment and suggest that a high level of expertise is required to fully assess ASD, individuals with FOXP1 syndrome will nevertheless likely benefit from similar treatments to those with ASD. In addition to interventions targeting repetitive behaviors, sensory symptoms, and compulsive-like behaviors, social skills training is likely warranted given the extent of social difficulties endorsed by caregivers across measures.</p>
<p id="Par52">In contrast to findings from previous studies [<xref ref-type="bibr" rid="CR1">1</xref>–<xref ref-type="bibr" rid="CR3">3</xref>], our results using norm-referenced language assessments indicate that expressive language is better developed than receptive language. Parents reported fewer skills in both expressive and receptive subdomains on the Vineland-II as compared to results from clinician-administered assessments (Expressive Vocabulary Test, 2nd Edition and Peabody Picture Vocabulary Test, 4<sup>th</sup> Edition). This discrepancy likely reflects differences between language ability and the application of language during daily functioning. Visual-motor integration and motor coordination deficits were also present in all individuals. Language and motor weaknesses appear to emerge early, as evidenced by delays in the achievement of developmental milestones.</p>
<p id="Par53">The wide age range of participants did appear to impact performance on standardized assessments, particularly cognitive testing. Within this cohort, the two youngest participants achieved the highest IQ scores and the oldest participant achieved the lowest IQ score. As individuals with developmental delays age, scores on standardized testing often declines due to an individual’s failure to gain new skills at the expected pace. Larger samples are needed to assess the progression of the syndrome and to better understand the variability in clinical presentation across patients.</p>
<p id="Par54">The individual with the <italic>FOXP1</italic> duplication presented with a similar phenotype, which included delays in reaching developmental milestones, borderline cognitive and adaptive functioning, visual-motor integration deficits, sub-threshold ASD symptoms, and clinically significant levels of anxiety (Additional file <xref ref-type="media" rid="MOESM1">1</xref>).</p>
<p id="Par55">On the neurological exam, fine and gross motor coordination deficits were present in all individuals, which is consistent with motor delays and continued deficits in the motor domain. Structural abnormalities on brain MRI were detected in the majority of individuals but did not follow a specific pattern. Enlarged ventricles were the most common imaging finding and this has been reported previously [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR20">20</xref>]. There was no report of seizure disorder in any individual.</p>
<p id="Par56">On the medical exam, we observed congenital heart defects in two out of six individuals examined. An association between congenital heart defects and <italic>FOXP1</italic> haploinsufficiency has been suggested in an earlier report [<xref ref-type="bibr" rid="CR63">63</xref>] and sporadically detected in affected individuals [<xref ref-type="bibr" rid="CR20">20</xref>], but not replicated in a large-scale WES study on congenital heart defects [<xref ref-type="bibr" rid="CR64">64</xref>]. Nevertheless, <italic>FOXP1</italic> plays a key role in cardiac morphogenesis in mice [<xref ref-type="bibr" rid="CR65">65</xref>] and cardiac problems should be assessed in individuals with <italic>FOXP1</italic> mutations. Another relevant medical finding is related to congenital anomalies of the kidney and urinary tract. A previous study reported eight individuals with de novo mutations in FOXP1, six of which had congenital anomalies of the kidney and urinary tract [<xref ref-type="bibr" rid="CR20">20</xref>]. One individual in our cohort had congenital renal defects. While genitourinary abnormalities were not reported in the other patients in our cohort, it remains important to consider kidney/urinary tract congenital anomalies when assessing individuals with FOXP1 syndrome. In addition, constipation was reported by several parents in our cohort and is often present in children with neurodevelopmental disorders, especially in conditions associated with hypotonia. On review of the medications used in our cohort, it does not appear that the extent of constipation can be accounted for by psychotropic medication use. The majority of individuals affected by constipation were either not receiving medications, or not receiving medications where constipation is a common side effect.</p>
<p id="Par57">On the dysmorphology exam, although non-specific, over half the cohort presented with several dysmorphic features including a broad nasal bridge, prominent forehead, bulbous nose, high arched palate, clinodactyly, strabismus, and hypertelorism (Fig. <xref ref-type="fig" rid="Fig4">4</xref>).</p>
<p id="Par58">Our genetic findings can also inform the design of patient-specific cellular models and animal models with stronger construct validity, which are at this point critical to understand the underpinnings of FOXP1 syndrome. Thus far, cultured rodent neurons have been employed to identify the defects in neuronal morphology and physiology resulting from <italic>FOXP1</italic> silencing [<xref ref-type="bibr" rid="CR66">66</xref>] or knockout [<xref ref-type="bibr" rid="CR32">32</xref>]. Also, the functional consequences of <italic>FOXP1</italic> mutations have been investigated only in non-neuronal cells. <italic>FOXP1</italic> mRNA harboring loss-of-function mutations are likely to undergo non-sense mediated decay, as shown for p.Ala339Serfs4* [<xref ref-type="bibr" rid="CR10">10</xref>], but at least a fraction of them escape non-sense mediated decay. Exogenously expressed FOXP1 mutants harboring p.Val423Hisfs*37 [<xref ref-type="bibr" rid="CR4">4</xref>], p.Ala339Serfs4* [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR10">10</xref>], p.Tyr439*, or p.Arg525* [<xref ref-type="bibr" rid="CR5">5</xref>] have been shown to disrupt nuclear localization. Missense mutations result in aberrant aggregates in the nucleus and cytoplasm (p.Arg514Cys and p.Arg465Gly) or only in the cytoplasm (p.Trp534Arg) [<xref ref-type="bibr" rid="CR5">5</xref>]. These eight mutations abolish the transcriptional repression activity of FOXP1, as shown by enhanced expression of a luciferase reporter [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR5">5</xref>]. While mutations p.Ala339Serfs4*, p.Arg525*, and p.Trp534Arg suppress the interaction with wildtype FOXP1 and FOXP2 [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR5">5</xref>], FOXP1 mutants carrying p.Tyr439*, p.Arg514Cys, or p.Arg465Gly retain the ability to bind FOXP1 and FOXP1 and might exert dominant-negative effects [<xref ref-type="bibr" rid="CR5">5</xref>]. Investigating neuronal models carrying recurrent pathogenic mutations or patient-derived human neuronal models is key to comprehensively expose the pathophysiological mechanisms underlying FOXP1 syndrome.</p>
<p id="Par59">Similarly, mouse models studied thus far have brain-specific knockout of <italic>FOXP1</italic> [<xref ref-type="bibr" rid="CR23">23</xref>, <xref ref-type="bibr" rid="CR32">32</xref>]. While these models have been instrumental in elucidating the fundamental role of <italic>FOXP1</italic> in the striatum and their relevance to some of the phenotypes observed in individuals, they recapitulate only in part the genetic architecture of FOXP1 syndrome. First, they accurately model only cases with <italic>FOXP1</italic> deletions rather than mutations. A strategy to mimic patient-specific mutations has been applied for <italic>FOXP2</italic> by generating a knockin mouse with the equivalent of the p.Arg553His human mutation (p.Arg514His in <italic>FOXP1</italic>) [<xref ref-type="bibr" rid="CR67">67</xref>]. Second, these studies have used homozygous animals, while the syndrome results from a heterozygous defect, rather than complete loss of <italic>FOXP1</italic>. The clinical evidence reported here might inform targeted phenotypic characterization of <italic>Foxp1</italic> rodent models to fully capture the clinical features of the syndrome, including the neurodevelopmental phenotype and the other medical co-morbidities. Based on the clinical phenotypes in individuals with FOXP1 syndrome, a comprehensive characterization of heterozygous <italic>FOXP1</italic> rodent models should include an examination of motor abnormalities, hyperactivity and executive functioning, repetitive and compulsive behaviors, social and communication deficits, cognitive changes, anxiety, and circadian/sleep abnormalities. Deficits in visual-motor integration would be particularly interesting to study. In addition, careful examination of cardiac, renal and visual organs, as well as brain ventricle size would be warranted. Finally, immune and endocrine function should be investigated.</p>
</sec>
<sec id="Sec26">
<title>Conclusions</title>
<p id="Par60">This study identifies novel <italic>FOXP1</italic> mutations associated with FOXP1 syndrome and identifies recurrent mutations as well as a significant clustering of missense mutations in the DNA-binding domain. These findings can be incorporated into clinical genetics practice to improve accurate genetic diagnosis of FOXP1 syndrome. This study also describes a phenotype characterized by motor and language delays (expressive language better developed than receptive language), visual-motor integration deficits, ASD symptoms, and associated features of anxiety, ADHD, obsessive-compulsive traits, and externalizing behavior. Intellectual and adaptive functioning ranged from profound ID to average, with evenly developed skills within individuals. Individuals identified to have a <italic>FOXP1</italic> mutation should begin behavioral interventions (e.g., physical therapy, speech and language therapy, occupational therapy) as early as possible, even before delays emerge. Psychiatric interventions will be critical to appropriately manage psychiatric symptoms as they arise. In order to make informed educational recommendations, future studies should assess academic achievement in individuals with FOXP1 syndrome. Natural history studies are also critical to examine the effects of FOXP1 syndrome throughout the lifespan in order to develop improved guidelines for medical assessment, monitoring, and treatment. The careful examination of model systems will lead to improved understanding of the pathophysiology of FOXP1 syndrome and can lead to novel therapeutic targets.</p>
</sec>
<sec sec-type="supplementary-material">
<title>Additional files</title>
<sec id="Sec27">
<p>
<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="13229_2017_172_MOESM1_ESM.docx"><label>Additional file 1:</label><caption><p>Supplementary note containing the genetic and clinical information for the individual with the <italic>FOXP1</italic> duplication. (DOCX 107 kb)</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM2"><media xlink:href="13229_2017_172_MOESM2_ESM.xlsx"><label>Additional file 2:</label><caption><p>Pathogenic <italic>FOXP1</italic> mutations reported in the literature and in ClinVar. (XLSX 24 kb)</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM3"><media xlink:href="13229_2017_172_MOESM3_ESM.docx"><label>Additional file 3:</label><caption><p>DSM-5 criteria for ASD in individuals with <italic>FOXP1</italic> mutations. (DOCX 18 kb)</p></caption></media></supplementary-material>
</p>
</sec>
</sec>
</body>
<back>
<fn-group>
<fn>
<p>
<bold>Electronic supplementary material</bold>
</p>
<p>The online version of this article (10.1186/s13229-017-0172-6) contains supplementary material, which is available to authorized users.</p>
</fn>
</fn-group>
<ack>
<title>Acknowledgements</title>
<p>We thank all the participants and their parents for their participation. We are grateful to the Whitney family for their support. We thank Danielle Halpern, PsyD, Lauren Donnelly, PhD, and Ting Wang, PhD for their assistance with data collection. We also thank Jennifer Reichert for her assistance with DNA isolation. The molecular graphics and analyses were performed with UCSF ChimeraX, developed by the Resource for Biocomputing, Visualization, and Informatics at the University of California, San Francisco (supported by NIGMS P41-GM103311).</p>
<sec id="FPar1">
<title>Funding</title>
<p id="Par61">This work was supported by the Whitney family and the Seaver Foundation. SDR is a Seaver Fellow. This work was also supported by the National Institutes of Mental Health (MH100047 to RAB and MH101221 to EEE). E.E.E. is an investigator of the Howard Hughes Medical Institute.</p>
</sec>
<sec id="FPar2">
<title>Availability of data and materials</title>
<p id="Par62">All data generated or analyzed during this study are included in this published article and its supplementary information files.</p>
</sec>
</ack>
<notes notes-type="author-contribution">
<title>Authors’ contributions</title>
<p>PMS, SDR, AK, and JDB conceived and designed the study. SDR analyzed and interpreted the genetic data. FM contributed molecular validation data and helped with data processing. DDM conducted the structural analyses. PMS, MPT and AK analyzed and interpreted the data regarding the psychiatric evaluation. MPT and AK analyzed and interpreted the data regarding the medical evaluation. YF analyzed and interpreted the data regarding the neurological evaluation. RL analyzed and interpreted the data regarding the dysmorphology exam. AD managed samples and clinical data. RAB was involved in study concept and design. EEE contributed gene variant data. RAB, HCM, MK, JG, ASW, and JB conducted phenotypic data collection for individuals W1-W4. RAB, MK, and JB were involved in manuscript preparation. AK and JDB supervised the study. PMS, SDR, AK, and JDB wrote the manuscript. All authors read and approved the final manuscript.</p>
</notes>
<notes notes-type="COI-statement">
<sec id="FPar3">
<title>Ethics approval and consent to participate</title>
<p id="Par63">The study was approved by the Institutional Review Boards at the Icahn School of Medicine at Mount Sinai and at the University of Washington. Parents or legal guardians provided informed consent for participation.</p>
</sec>
<sec id="FPar4">
<title>Consent for publication</title>
<p id="Par64">Written informed consent was obtained from parents or legal guardians of participants for publication of participants’ individuals details and accompanying images in this manuscript. The consent forms are held by the authors’ institutions in the patients’ clinical notes and are available for review by the Editor-in-Chief.</p>
</sec>
<sec id="FPar5">
<title>Competing interests</title>
<p id="Par65">The authors declare that they have no competing interests.</p>
</sec>
<sec id="FPar6">
<title>Publisher’s Note</title>
<p id="Par66">Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p>
</sec>
</notes>
<ref-list id="Bib1">
<title>References</title>
<ref id="CR1">
<label>1.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hamdan</surname>
<given-names>FF</given-names>
</name>
<name>
<surname>Daoud</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Rochefort</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Piton</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Gauthier</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Langlois</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Foomani</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Dobrzeniecka</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Krebs</surname>
<given-names>MO</given-names>
</name>
<name>
<surname>Joober</surname>
<given-names>R</given-names>
</name>
<etal></etal>
</person-group>
<article-title>De novo mutations in FOXP1 in cases with intellectual disability, autism, and language impairment</article-title>
<source/>Am J Hum Genet
          <year>2010</year>
<volume>87</volume>
<fpage>671</fpage>
<lpage>678</lpage>
<pub-id pub-id-type="doi">10.1016/j.ajhg.2010.09.017</pub-id>
<pub-id pub-id-type="pmid">20950788</pub-id>
</element-citation>
</ref>
<ref id="CR2">
<label>2.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Horn</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Kapeller</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Rivera-Brugues</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Moog</surname>
<given-names>U</given-names>
</name>
<name>
<surname>Lorenz-Depiereux</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Eck</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Hempel</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Wagenstaller</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Gawthrope</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Monaco</surname>
<given-names>AP</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Identification of FOXP1 deletions in three unrelated patients with mental retardation and significant speech and language deficits</article-title>
<source/>Hum Mutat
          <year>2010</year>
<volume>31</volume>
<fpage>E1851</fpage>
<lpage>E1860</lpage>
<pub-id pub-id-type="doi">10.1002/humu.21362</pub-id>
<pub-id pub-id-type="pmid">20848658</pub-id>
</element-citation>
</ref>
<ref id="CR3">
<label>3.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Le Fevre</surname>
<given-names>AK</given-names>
</name>
<name>
<surname>Taylor</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Malek</surname>
<given-names>NH</given-names>
</name>
<name>
<surname>Horn</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Carr</surname>
<given-names>CW</given-names>
</name>
<name>
<surname>Abdul-Rahman</surname>
<given-names>OA</given-names>
</name>
<name>
<surname>O'Donnell</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Burgess</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Shaw</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Gecz</surname>
<given-names>J</given-names>
</name>
<etal></etal>
</person-group>
<article-title>FOXP1 mutations cause intellectual disability and a recognizable phenotype</article-title>
<source/>Am J Med Genet A
          <year>2013</year>
<volume>161A</volume>
<fpage>3166</fpage>
<lpage>3175</lpage>
<pub-id pub-id-type="doi">10.1002/ajmg.a.36174</pub-id>
<pub-id pub-id-type="pmid">24214399</pub-id>
</element-citation>
</ref>
<ref id="CR4">
<label>4.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lozano</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Vino</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Lozano</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Fisher</surname>
<given-names>SE</given-names>
</name>
<name>
<surname>Deriziotis</surname>
<given-names>P</given-names>
</name>
</person-group>
<article-title>A de novo FOXP1 variant in a patient with autism, intellectual disability and severe speech and language impairment</article-title>
<source/>Eur J Hum Genet
          <year>2015</year>
<volume>23</volume>
<fpage>1702</fpage>
<lpage>1707</lpage>
<pub-id pub-id-type="doi">10.1038/ejhg.2015.66</pub-id>
<pub-id pub-id-type="pmid">25853299</pub-id>
</element-citation>
</ref>
<ref id="CR5">
<label>5.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sollis</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Graham</surname>
<given-names>SA</given-names>
</name>
<name>
<surname>Vino</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Froehlich</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Vreeburg</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Dimitropoulou</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Gilissen</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Pfundt</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Rappold</surname>
<given-names>GA</given-names>
</name>
<name>
<surname>Brunner</surname>
<given-names>HG</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Identification and functional characterization of de novo FOXP1 variants provides novel insights into the etiology of neurodevelopmental disorder</article-title>
<source/>Hum Mol Genet
          <year>2016</year>
<volume>25</volume>
<fpage>546</fpage>
<lpage>557</lpage>
<pub-id pub-id-type="doi">10.1093/hmg/ddv495</pub-id>
<pub-id pub-id-type="pmid">26647308</pub-id>
</element-citation>
</ref>
<ref id="CR6">
<label>6.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pariani</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Spencer</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Graham</surname>
<given-names>JM</given-names>
<suffix>Jr</suffix>
</name>
<name>
<surname>Rimoin</surname>
<given-names>DL</given-names>
</name>
</person-group>
<article-title>A 785kb deletion of 3p14.1p13, including the FOXP1 gene, associated with speech delay, contractures, hypertonia and blepharophimosis</article-title>
<source/>Eur J Med Genet
          <year>2009</year>
<volume>52</volume>
<fpage>123</fpage>
<lpage>127</lpage>
<pub-id pub-id-type="doi">10.1016/j.ejmg.2009.03.012</pub-id>
<pub-id pub-id-type="pmid">19332160</pub-id>
</element-citation>
</ref>
<ref id="CR7">
<label>7.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Carr</surname>
<given-names>CW</given-names>
</name>
<name>
<surname>Moreno-De-Luca</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Parker</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Zimmerman</surname>
<given-names>HH</given-names>
</name>
<name>
<surname>Ledbetter</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Martin</surname>
<given-names>CL</given-names>
</name>
<name>
<surname>Dobyns</surname>
<given-names>WB</given-names>
</name>
<name>
<surname>Abdul-Rahman</surname>
<given-names>OA</given-names>
</name>
</person-group>
<article-title>Chiari I malformation, delayed gross motor skills, severe speech delay, and epileptiform discharges in a child with FOXP1 haploinsufficiency</article-title>
<source/>Eur J Hum Genet
          <year>2010</year>
<volume>18</volume>
<fpage>1216</fpage>
<lpage>1220</lpage>
<pub-id pub-id-type="doi">10.1038/ejhg.2010.96</pub-id>
<pub-id pub-id-type="pmid">20571508</pub-id>
</element-citation>
</ref>
<ref id="CR8">
<label>8.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Palumbo</surname>
<given-names>O</given-names>
</name>
<name>
<surname>D'Agruma</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Minenna</surname>
<given-names>AF</given-names>
</name>
<name>
<surname>Palumbo</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Stallone</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Palladino</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Zelante</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Carella</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>3p14.1 de novo microdeletion involving the FOXP1 gene in an adult patient with autism, severe speech delay and deficit of motor coordination</article-title>
<source/>Gene
          <year>2013</year>
<volume>516</volume>
<fpage>107</fpage>
<lpage>113</lpage>
<pub-id pub-id-type="doi">10.1016/j.gene.2012.12.073</pub-id>
<pub-id pub-id-type="pmid">23287644</pub-id>
</element-citation>
</ref>
<ref id="CR9">
<label>9.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Worthey</surname>
<given-names>EA</given-names>
</name>
<name>
<surname>Raca</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Laffin</surname>
<given-names>JJ</given-names>
</name>
<name>
<surname>Wilk</surname>
<given-names>BM</given-names>
</name>
<name>
<surname>Harris</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Jakielski</surname>
<given-names>KJ</given-names>
</name>
<name>
<surname>Dimmock</surname>
<given-names>DP</given-names>
</name>
<name>
<surname>Strand</surname>
<given-names>EA</given-names>
</name>
<name>
<surname>Shriberg</surname>
<given-names>LD</given-names>
</name>
</person-group>
<article-title>Whole-exome sequencing supports genetic heterogeneity in childhood apraxia of speech</article-title>
<source/>J Neurodev Disord
          <year>2013</year>
<volume>5</volume>
<fpage>29</fpage>
<pub-id pub-id-type="doi">10.1186/1866-1955-5-29</pub-id>
<pub-id pub-id-type="pmid">24083349</pub-id>
</element-citation>
</ref>
<ref id="CR10">
<label>10.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>O'Roak</surname>
<given-names>BJ</given-names>
</name>
<name>
<surname>Deriziotis</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Vives</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Schwartz</surname>
<given-names>JJ</given-names>
</name>
<name>
<surname>Girirajan</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Karakoc</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Mackenzie</surname>
<given-names>AP</given-names>
</name>
<name>
<surname>Ng</surname>
<given-names>SB</given-names>
</name>
<name>
<surname>Baker</surname>
<given-names>C</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Exome sequencing in sporadic autism spectrum disorders identifies severe de novo mutations</article-title>
<source/>Nat Genet
          <year>2011</year>
<volume>43</volume>
<fpage>585</fpage>
<lpage>589</lpage>
<pub-id pub-id-type="doi">10.1038/ng.835</pub-id>
<pub-id pub-id-type="pmid">21572417</pub-id>
</element-citation>
</ref>
<ref id="CR11">
<label>11.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Grozeva</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Carss</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Spasic-Boskovic</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Tejada</surname>
<given-names>MI</given-names>
</name>
<name>
<surname>Gecz</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Shaw</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Corbett</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Haan</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Thompson</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Friend</surname>
<given-names>K</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Targeted Next-Generation Sequencing Analysis of 1,000 Individuals with Intellectual Disability</article-title>
<source/>Hum Mutat
          <year>2015</year>
<volume>36</volume>
<fpage>1197</fpage>
<lpage>1204</lpage>
<pub-id pub-id-type="doi">10.1002/humu.22901</pub-id>
<pub-id pub-id-type="pmid">26350204</pub-id>
</element-citation>
</ref>
<ref id="CR12">
<label>12.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<collab>Deciphering Developmental Disorders Study</collab>
</person-group>
<article-title>Prevalence and architecture of de novo mutations in developmental disorders</article-title>
<source/>Nature
          <year>2017</year>
<volume>542</volume>
<fpage>433</fpage>
<lpage>438</lpage>
<pub-id pub-id-type="doi">10.1038/nature21062</pub-id>
<pub-id pub-id-type="pmid">28135719</pub-id>
</element-citation>
</ref>
<ref id="CR13">
<label>13.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Srivastava</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Cohen</surname>
<given-names>JS</given-names>
</name>
<name>
<surname>Vernon</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Baranano</surname>
<given-names>K</given-names>
</name>
<name>
<surname>McClellan</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Jamal</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Naidu</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Fatemi</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Clinical whole exome sequencing in child neurology practice</article-title>
<source/>Ann Neurol
          <year>2014</year>
<volume>76</volume>
<fpage>473</fpage>
<lpage>483</lpage>
<pub-id pub-id-type="doi">10.1002/ana.24251</pub-id>
<pub-id pub-id-type="pmid">25131622</pub-id>
</element-citation>
</ref>
<ref id="CR14">
<label>14.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Iossifov</surname>
<given-names>I</given-names>
</name>
<name>
<surname>O'Roak</surname>
<given-names>BJ</given-names>
</name>
<name>
<surname>Sanders</surname>
<given-names>SJ</given-names>
</name>
<name>
<surname>Ronemus</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Krumm</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Levy</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Stessman</surname>
<given-names>HA</given-names>
</name>
<name>
<surname>Witherspoon</surname>
<given-names>KT</given-names>
</name>
<name>
<surname>Vives</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Patterson</surname>
<given-names>KE</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The contribution of de novo coding mutations to autism spectrum disorder</article-title>
<source/>Nature
          <year>2014</year>
<volume>515</volume>
<fpage>216</fpage>
<lpage>221</lpage>
<pub-id pub-id-type="doi">10.1038/nature13908</pub-id>
<pub-id pub-id-type="pmid">25363768</pub-id>
</element-citation>
</ref>
<ref id="CR15">
<label>15.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yuen</surname>
<given-names>RK</given-names>
</name>
<name>
<surname>Merico</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Bookman</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Howe</surname>
<given-names>LJ</given-names>
</name>
<name>
<surname>Thiruvahindrapuram</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Patel</surname>
<given-names>RV</given-names>
</name>
<name>
<surname>Whitney</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Deflaux</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Bingham</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Z</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Whole genome sequencing resource identifies 18 new candidate genes for autism spectrum disorder</article-title>
<source/>Nat Neurosci
          <year>2017</year>
<volume>20</volume>
<fpage>602</fpage>
<lpage>611</lpage>
<pub-id pub-id-type="doi">10.1038/nn.4524</pub-id>
<pub-id pub-id-type="pmid">28263302</pub-id>
</element-citation>
</ref>
<ref id="CR16">
<label>16.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tutulan-Cunita</surname>
<given-names>AC</given-names>
</name>
<name>
<surname>Papuc</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>Arghir</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Rotzer</surname>
<given-names>KM</given-names>
</name>
<name>
<surname>Deshpande</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Lungeanu</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Budisteanu</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>3p interstitial deletion: novel case report and review</article-title>
<source/>J Child Neurol
          <year>2012</year>
<volume>27</volume>
<fpage>1062</fpage>
<lpage>1066</lpage>
<pub-id pub-id-type="doi">10.1177/0883073811431016</pub-id>
<pub-id pub-id-type="pmid">22290856</pub-id>
</element-citation>
</ref>
<ref id="CR17">
<label>17.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dimitrov</surname>
<given-names>BI</given-names>
</name>
<name>
<surname>Ogilvie</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Wieczorek</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Wakeling</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Sikkema-Raddatz</surname>
<given-names>B</given-names>
</name>
<name>
<surname>van Ravenswaaij-Arts</surname>
<given-names>CM</given-names>
</name>
<name>
<surname>Josifova</surname>
<given-names>D</given-names>
</name>
</person-group>
<article-title>3p14 deletion is a rare contiguous gene syndrome: report of 2 new patients and an overview of 14 patients</article-title>
<source/>Am J Med Genet A
          <year>2015</year>
<volume>167</volume>
<fpage>1223</fpage>
<lpage>1230</lpage>
<pub-id pub-id-type="doi">10.1002/ajmg.a.36556</pub-id>
<pub-id pub-id-type="pmid">25908055</pub-id>
</element-citation>
</ref>
<ref id="CR18">
<label>18.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schwarzbraun</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Ofner</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Gillessen-Kaesbach</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Schaperdoth</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Preisegger</surname>
<given-names>KH</given-names>
</name>
<name>
<surname>Windpassinger</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Wagner</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Petek</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Kroisel</surname>
<given-names>PM</given-names>
</name>
</person-group>
<article-title>A new 3p interstitial deletion including the entire MITF gene causes a variation of Tietz/Waardenburg type IIA syndromes</article-title>
<source/>Am J Med Genet A
          <year>2007</year>
<volume>143A</volume>
<fpage>619</fpage>
<lpage>624</lpage>
<pub-id pub-id-type="doi">10.1002/ajmg.a.31627</pub-id>
<pub-id pub-id-type="pmid">17318840</pub-id>
</element-citation>
</ref>
<ref id="CR19">
<label>19.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<collab>Autism Spectrum Disorders Working Group of The Psychiatric Genomics Consortium</collab>
</person-group>
<article-title>Meta-analysis of GWAS of over 16,000 individuals with autism spectrum disorder highlights a novel locus at 10q24.32 and a significant overlap with schizophrenia</article-title>
<source/>Mol Autism
          <year>2017</year>
<volume>8</volume>
<fpage>21</fpage>
<pub-id pub-id-type="doi">10.1186/s13229-017-0137-9</pub-id>
<pub-id pub-id-type="pmid">28540026</pub-id>
</element-citation>
</ref>
<ref id="CR20">
<label>20.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bekheirnia</surname>
<given-names>MR</given-names>
</name>
<name>
<surname>Bekheirnia</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Bainbridge</surname>
<given-names>MN</given-names>
</name>
<name>
<surname>Gu</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Coban Akdemir</surname>
<given-names>ZH</given-names>
</name>
<name>
<surname>Gambin</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Janzen</surname>
<given-names>NK</given-names>
</name>
<name>
<surname>Jhangiani</surname>
<given-names>SN</given-names>
</name>
<name>
<surname>Muzny</surname>
<given-names>DM</given-names>
</name>
<name>
<surname>Michael</surname>
<given-names>M</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Whole-exome sequencing in the molecular diagnosis of individuals with congenital anomalies of the kidney and urinary tract and identification of a new causative gene</article-title>
<source/>Genet Med
          <year>2017</year>
<volume>19</volume>
<fpage>412</fpage>
<lpage>420</lpage>
<pub-id pub-id-type="doi">10.1038/gim.2016.131</pub-id>
<pub-id pub-id-type="pmid">27657687</pub-id>
</element-citation>
</ref>
<ref id="CR21">
<label>21.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shu</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>MM</given-names>
</name>
<name>
<surname>Morrisey</surname>
<given-names>EE</given-names>
</name>
</person-group>
<article-title>Characterization of a new subfamily of winged-helix/forkhead (Fox) genes that are expressed in the lung and act as transcriptional repressors</article-title>
<source/>J Biol Chem
          <year>2001</year>
<volume>276</volume>
<fpage>27488</fpage>
<lpage>27497</lpage>
<pub-id pub-id-type="doi">10.1074/jbc.M100636200</pub-id>
<pub-id pub-id-type="pmid">11358962</pub-id>
</element-citation>
</ref>
<ref id="CR22">
<label>22.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Teramitsu</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Kudo</surname>
<given-names>LC</given-names>
</name>
<name>
<surname>London</surname>
<given-names>SE</given-names>
</name>
<name>
<surname>Geschwind</surname>
<given-names>DH</given-names>
</name>
<name>
<surname>White</surname>
<given-names>SA</given-names>
</name>
</person-group>
<article-title>Parallel FoxP1 and FoxP2 expression in songbird and human brain predicts functional interaction</article-title>
<source/>J Neurosci
          <year>2004</year>
<volume>24</volume>
<fpage>3152</fpage>
<lpage>3163</lpage>
<pub-id pub-id-type="doi">10.1523/JNEUROSCI.5589-03.2004</pub-id>
<pub-id pub-id-type="pmid">15056695</pub-id>
</element-citation>
</ref>
<ref id="CR23">
<label>23.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Frohlich</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Rafiullah</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Schmitt</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Abele</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Rappold</surname>
<given-names>GA</given-names>
</name>
</person-group>
<article-title>Foxp1 expression is essential for sex-specific murine neonatal ultrasonic vocalization</article-title>
<source/>Hum Mol Genet
          <year>2017</year>
<volume>26</volume>
<fpage>1511</fpage>
<lpage>1521</lpage>
<pub-id pub-id-type="doi">10.1093/hmg/ddx055</pub-id>
<pub-id pub-id-type="pmid">28204507</pub-id>
</element-citation>
</ref>
<ref id="CR24">
<label>24.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Feuk</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Kalervo</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Lipsanen-Nyman</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Skaug</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Nakabayashi</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Finucane</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Hartung</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Innes</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Kerem</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Nowaczyk</surname>
<given-names>MJ</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Absence of a paternally inherited FOXP2 gene in developmental verbal dyspraxia</article-title>
<source/>Am J Hum Genet
          <year>2006</year>
<volume>79</volume>
<fpage>965</fpage>
<lpage>972</lpage>
<pub-id pub-id-type="doi">10.1086/508902</pub-id>
<pub-id pub-id-type="pmid">17033973</pub-id>
</element-citation>
</ref>
<ref id="CR25">
<label>25.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zeesman</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Nowaczyk</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Teshima</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Roberts</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Cardy</surname>
<given-names>JO</given-names>
</name>
<name>
<surname>Brian</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Senman</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Feuk</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Osborne</surname>
<given-names>LR</given-names>
</name>
<name>
<surname>Scherer</surname>
<given-names>SW</given-names>
</name>
</person-group>
<article-title>Speech and language impairment and oromotor dyspraxia due to deletion of 7q31 that involves FOXP2</article-title>
<source/>Am J Med Genet A
          <year>2006</year>
<volume>140</volume>
<fpage>509</fpage>
<lpage>514</lpage>
<pub-id pub-id-type="doi">10.1002/ajmg.a.31110</pub-id>
<pub-id pub-id-type="pmid">16470794</pub-id>
</element-citation>
</ref>
<ref id="CR26">
<label>26.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lai</surname>
<given-names>CS</given-names>
</name>
<name>
<surname>Fisher</surname>
<given-names>SE</given-names>
</name>
<name>
<surname>Hurst</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Vargha-Khadem</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Monaco</surname>
<given-names>AP</given-names>
</name>
</person-group>
<article-title>A forkhead-domain gene is mutated in a severe speech and language disorder</article-title>
<source/>Nature
          <year>2001</year>
<volume>413</volume>
<fpage>519</fpage>
<lpage>523</lpage>
<pub-id pub-id-type="doi">10.1038/35097076</pub-id>
<pub-id pub-id-type="pmid">11586359</pub-id>
</element-citation>
</ref>
<ref id="CR27">
<label>27.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>MacDermot</surname>
<given-names>KD</given-names>
</name>
<name>
<surname>Bonora</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Sykes</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Coupe</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Lai</surname>
<given-names>CS</given-names>
</name>
<name>
<surname>Vernes</surname>
<given-names>SC</given-names>
</name>
<name>
<surname>Vargha-Khadem</surname>
<given-names>F</given-names>
</name>
<name>
<surname>McKenzie</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Smith</surname>
<given-names>RL</given-names>
</name>
<name>
<surname>Monaco</surname>
<given-names>AP</given-names>
</name>
<name>
<surname>Fisher</surname>
<given-names>SE</given-names>
</name>
</person-group>
<article-title>Identification of FOXP2 truncation as a novel cause of developmental speech and language deficits</article-title>
<source/>Am J Hum Genet
          <year>2005</year>
<volume>76</volume>
<fpage>1074</fpage>
<lpage>1080</lpage>
<pub-id pub-id-type="doi">10.1086/430841</pub-id>
<pub-id pub-id-type="pmid">15877281</pub-id>
</element-citation>
</ref>
<ref id="CR28">
<label>28.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Xiao</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Frohlich</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Tu</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Cao</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Qu</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Rappold</surname>
<given-names>GA</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>JG</given-names>
</name>
</person-group>
<article-title>Foxp1 regulates cortical radial migration and neuronal morphogenesis in developing cerebral cortex</article-title>
<source/>PLoS One
          <year>2015</year>
<volume>10</volume>
<fpage>e0127671</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pone.0127671</pub-id>
<pub-id pub-id-type="pmid">26010426</pub-id>
</element-citation>
</ref>
<ref id="CR29">
<label>29.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ferland</surname>
<given-names>RJ</given-names>
</name>
<name>
<surname>Cherry</surname>
<given-names>TJ</given-names>
</name>
<name>
<surname>Preware</surname>
<given-names>PO</given-names>
</name>
<name>
<surname>Morrisey</surname>
<given-names>EE</given-names>
</name>
<name>
<surname>Walsh</surname>
<given-names>CA</given-names>
</name>
</person-group>
<article-title>Characterization of Foxp2 and Foxp1 mRNA and protein in the developing and mature brain</article-title>
<source/>J Comp Neurol
          <year>2003</year>
<volume>460</volume>
<fpage>266</fpage>
<lpage>279</lpage>
<pub-id pub-id-type="doi">10.1002/cne.10654</pub-id>
<pub-id pub-id-type="pmid">12687690</pub-id>
</element-citation>
</ref>
<ref id="CR30">
<label>30.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tsui</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Vessey</surname>
<given-names>JP</given-names>
</name>
<name>
<surname>Tomita</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Kaplan</surname>
<given-names>DR</given-names>
</name>
<name>
<surname>Miller</surname>
<given-names>FD</given-names>
</name>
</person-group>
<article-title>FoxP2 regulates neurogenesis during embryonic cortical development</article-title>
<source/>J Neurosci
          <year>2013</year>
<volume>33</volume>
<fpage>244</fpage>
<lpage>258</lpage>
<pub-id pub-id-type="doi">10.1523/JNEUROSCI.1665-12.2013</pub-id>
<pub-id pub-id-type="pmid">23283338</pub-id>
</element-citation>
</ref>
<ref id="CR31">
<label>31.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shu</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Cho</surname>
<given-names>JY</given-names>
</name>
<name>
<surname>Jiang</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Weisz</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Elder</surname>
<given-names>GA</given-names>
</name>
<name>
<surname>Schmeidler</surname>
<given-names>J</given-names>
</name>
<name>
<surname>De Gasperi</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Sosa</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Rabidou</surname>
<given-names>D</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Altered ultrasonic vocalization in mice with a disruption in the Foxp2 gene</article-title>
<source/>Proc Natl Acad Sci U S A
          <year>2005</year>
<volume>102</volume>
<fpage>9643</fpage>
<lpage>9648</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.0503739102</pub-id>
<pub-id pub-id-type="pmid">15983371</pub-id>
</element-citation>
</ref>
<ref id="CR32">
<label>32.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bacon</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Schneider</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Le Magueresse</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Froehlich</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Sticht</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Gluch</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Monyer</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Rappold</surname>
<given-names>GA</given-names>
</name>
</person-group>
<article-title>Brain-specific Foxp1 deletion impairs neuronal development and causes autistic-like behaviour</article-title>
<source/>Mol Psychiatry
          <year>2015</year>
<volume>20</volume>
<fpage>632</fpage>
<lpage>639</lpage>
<pub-id pub-id-type="doi">10.1038/mp.2014.116</pub-id>
<pub-id pub-id-type="pmid">25266127</pub-id>
</element-citation>
</ref>
<ref id="CR33">
<label>33.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Blanco Sanchez</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Duat Rodriguez</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Cantarin Extremera</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Lapunzina</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Palomares Bralo</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Nevado</surname>
<given-names>BJ</given-names>
</name>
</person-group>
<article-title>Clinical phenotype of a patient with FOXP1 deletion</article-title>
<source/>An Pediatr (Barc)
          <year>2015</year>
<volume>82</volume>
<fpage>280</fpage>
<lpage>281</lpage>
<pub-id pub-id-type="doi">10.1016/j.anpedi.2014.06.007</pub-id>
<pub-id pub-id-type="pmid">25037997</pub-id>
</element-citation>
</ref>
<ref id="CR34">
<label>34.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lloveras</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Vendrell</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Fernandez</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Castells</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Cueto</surname>
<given-names>A</given-names>
</name>
<name>
<surname>del Campo</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Hernando</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Villa</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Plaja</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Intrachromosomal 3p insertion as a cause of reciprocal pure interstitial deletion and duplication in two siblings: further delineation of the emerging proximal 3p deletion syndrome</article-title>
<source/>Cytogenet Genome Res
          <year>2014</year>
<volume>144</volume>
<fpage>290</fpage>
<lpage>293</lpage>
<pub-id pub-id-type="doi">10.1159/000375184</pub-id>
<pub-id pub-id-type="pmid">25720458</pub-id>
</element-citation>
</ref>
<ref id="CR35">
<label>35.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>den Dunnen</surname>
<given-names>JT</given-names>
</name>
<name>
<surname>Dalgleish</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Maglott</surname>
<given-names>DR</given-names>
</name>
<name>
<surname>Hart</surname>
<given-names>RK</given-names>
</name>
<name>
<surname>Greenblatt</surname>
<given-names>MS</given-names>
</name>
<name>
<surname>McGowan-Jordan</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Roux</surname>
<given-names>AF</given-names>
</name>
<name>
<surname>Smith</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Antonarakis</surname>
<given-names>SE</given-names>
</name>
<name>
<surname>Taschner</surname>
<given-names>PE</given-names>
</name>
</person-group>
<article-title>HGVS recommendations for the description of sequence variants: 2016 update</article-title>
<source/>Hum Mutat
          <year>2016</year>
<volume>37</volume>
<fpage>564</fpage>
<lpage>569</lpage>
<pub-id pub-id-type="doi">10.1002/humu.22981</pub-id>
<pub-id pub-id-type="pmid">26931183</pub-id>
</element-citation>
</ref>
<ref id="CR36">
<label>36.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Turner</surname>
<given-names>TN</given-names>
</name>
<name>
<surname>Yi</surname>
<given-names>Q</given-names>
</name>
<name>
<surname>Krumm</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Huddleston</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Hoekzema</surname>
<given-names>K</given-names>
</name>
<name>
<surname>HAF</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Doebley</surname>
<given-names>AL</given-names>
</name>
<name>
<surname>Bernier</surname>
<given-names>RA</given-names>
</name>
<name>
<surname>Nickerson</surname>
<given-names>DA</given-names>
</name>
<name>
<surname>Eichler</surname>
<given-names>EE</given-names>
</name>
</person-group>
<article-title>denovo-db: a compendium of human de novo variants</article-title>
<source/>Nucleic Acids Res
          <year>2017</year>
<volume>45</volume>
<fpage>D804</fpage>
<lpage>D811</lpage>
<pub-id pub-id-type="doi">10.1093/nar/gkw865</pub-id>
<pub-id pub-id-type="pmid">27907889</pub-id>
</element-citation>
</ref>
<ref id="CR37">
<label>37.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chu</surname>
<given-names>YP</given-names>
</name>
<name>
<surname>Chang</surname>
<given-names>CH</given-names>
</name>
<name>
<surname>Shiu</surname>
<given-names>JH</given-names>
</name>
<name>
<surname>Chang</surname>
<given-names>YT</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>CY</given-names>
</name>
<name>
<surname>Chuang</surname>
<given-names>WJ</given-names>
</name>
</person-group>
<article-title>Solution structure and backbone dynamics of the DNA-binding domain of FOXP1: insight into its domain swapping and DNA binding</article-title>
<source/>Protein Sci
          <year>2011</year>
<volume>20</volume>
<fpage>908</fpage>
<lpage>924</lpage>
<pub-id pub-id-type="doi">10.1002/pro.626</pub-id>
<pub-id pub-id-type="pmid">21416545</pub-id>
</element-citation>
</ref>
<ref id="CR38">
<label>38.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stroud</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Bates</surname>
<given-names>DL</given-names>
</name>
<name>
<surname>Han</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Nowick</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Paabo</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Tong</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>L</given-names>
</name>
</person-group>
<article-title>Structure of the forkhead domain of FOXP2 bound to DNA</article-title>
<source/>Structure
          <year>2006</year>
<volume>14</volume>
<fpage>159</fpage>
<lpage>166</lpage>
<pub-id pub-id-type="doi">10.1016/j.str.2005.10.005</pub-id>
<pub-id pub-id-type="pmid">16407075</pub-id>
</element-citation>
</ref>
<ref id="CR39">
<label>39.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pettersen</surname>
<given-names>EF</given-names>
</name>
<name>
<surname>Goddard</surname>
<given-names>TD</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>CC</given-names>
</name>
<name>
<surname>Couch</surname>
<given-names>GS</given-names>
</name>
<name>
<surname>Greenblatt</surname>
<given-names>DM</given-names>
</name>
<name>
<surname>Meng</surname>
<given-names>EC</given-names>
</name>
<name>
<surname>Ferrin</surname>
<given-names>TE</given-names>
</name>
</person-group>
<article-title>UCSF Chimera--a visualization system for exploratory research and analysis</article-title>
<source/>J Comput Chem
          <year>2004</year>
<volume>25</volume>
<fpage>1605</fpage>
<lpage>1612</lpage>
<pub-id pub-id-type="doi">10.1002/jcc.20084</pub-id>
<pub-id pub-id-type="pmid">15264254</pub-id>
</element-citation>
</ref>
<ref id="CR40">
<label>40.</label>
<element-citation publication-type="book">
<person-group person-group-type="author">
<name>
<surname>Lord</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Rutter</surname>
<given-names>M</given-names>
</name>
<name>
<surname>DiLavore</surname>
<given-names>PC</given-names>
</name>
<name>
<surname>Risi</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Gotham</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Bishop</surname>
<given-names>SL</given-names>
</name>
</person-group>
<source/>Autism Diagnostic Observation Schedule, Second Edition (ADOS-2) Manual (Part I): Modules 1–4
          <year>2012</year>
<publisher-loc>Western Psychological Services</publisher-loc>
<publisher-name>Torrance</publisher-name>
</element-citation>
</ref>
<ref id="CR41">
<label>41.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lord</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Rutter</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Le Couteur</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Autism Diagnostic Interview-Revised: a revised version of a diagnostic interview for caregivers of individuals with possible pervasive developmental disorders</article-title>
<source/>J Autism Dev Disord
          <year>1994</year>
<volume>24</volume>
<fpage>659</fpage>
<lpage>685</lpage>
<pub-id pub-id-type="doi">10.1007/BF02172145</pub-id>
<pub-id pub-id-type="pmid">7814313</pub-id>
</element-citation>
</ref>
<ref id="CR42">
<label>42.</label>
<element-citation publication-type="book">
<person-group person-group-type="author">
<name>
<surname>Rutter</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Le Couteur</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Lord</surname>
<given-names>C</given-names>
</name>
</person-group>
<source/>Autism Diagnostic Interview-Revised (ADI-R) Manual
          <year>2003</year>
<publisher-loc>Western Psychological Services</publisher-loc>
<publisher-name>Los Angeles</publisher-name>
</element-citation>
</ref>
<ref id="CR43">
<label>43.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hus</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Gotham</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Lord</surname>
<given-names>C</given-names>
</name>
</person-group>
<article-title>Standardizing ADOS domain scores: separating severity of social affect and restricted and repetitive behaviors</article-title>
<source/>J Autism Dev Disord
          <year>2014</year>
<volume>44</volume>
<fpage>2400</fpage>
<lpage>2412</lpage>
<pub-id pub-id-type="doi">10.1007/s10803-012-1719-1</pub-id>
<pub-id pub-id-type="pmid">23143131</pub-id>
</element-citation>
</ref>
<ref id="CR44">
<label>44.</label>
<element-citation publication-type="book">
<person-group person-group-type="author">
<name>
<surname>Constantino</surname>
<given-names>JN</given-names>
</name>
<name>
<surname>Gruber</surname>
<given-names>CP</given-names>
</name>
</person-group>
<source/>Social Responsiveness Scale, Second Edition (SRS-2)
          <year>2012</year>
<publisher-loc>Torrance</publisher-loc>
<publisher-name>Western Psychological Services</publisher-name>
</element-citation>
</ref>
<ref id="CR45">
<label>45.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bodfish</surname>
<given-names>JW</given-names>
</name>
<name>
<surname>Symons</surname>
<given-names>FJ</given-names>
</name>
<name>
<surname>Parker</surname>
<given-names>DE</given-names>
</name>
<name>
<surname>Lewis</surname>
<given-names>MH</given-names>
</name>
</person-group>
<article-title>Varieties of repetitive behavior in autism: comparisons to mental retardation</article-title>
<source/>J Autism Dev Disord
          <year>2000</year>
<volume>30</volume>
<fpage>237</fpage>
<lpage>243</lpage>
<pub-id pub-id-type="doi">10.1023/A:1005596502855</pub-id>
<pub-id pub-id-type="pmid">11055459</pub-id>
</element-citation>
</ref>
<ref id="CR46">
<label>46.</label>
<mixed-citation publication-type="other">Bodfish JW, Symons FJ, Lewis MH. The Repetitive Behavior Scale. Western Carolina Center Research Reports; 1999.</mixed-citation>
</ref>
<ref id="CR47">
<label>47.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dunn</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Westman</surname>
<given-names>K</given-names>
</name>
</person-group>
<article-title>The Sensory Profile: The performance of a national sample of children without disabilities</article-title>
<source/>Am J Occupational Ther
          <year>1997</year>
<volume>51</volume>
<fpage>25</fpage>
<lpage>34</lpage>
<pub-id pub-id-type="doi">10.5014/ajot.51.1.25</pub-id>
</element-citation>
</ref>
<ref id="CR48">
<label>48.</label>
<element-citation publication-type="book">
<person-group person-group-type="author">
<name>
<surname>Roid</surname>
<given-names>GH</given-names>
</name>
</person-group>
<source/>Stanford-Binet Intelligence Scales
          <year>2003</year>
<edition>5</edition>
<publisher-loc>Itasca</publisher-loc>
<publisher-name>Riverside Publishing</publisher-name>
</element-citation>
</ref>
<ref id="CR49">
<label>49.</label>
<element-citation publication-type="book">
<person-group person-group-type="author">
<name>
<surname>Elliot</surname>
<given-names>CD</given-names>
</name>
</person-group>
<source/>Differential Ability Scales-Second Edition
          <year>2007</year>
<publisher-loc>Introductory and Technical Manual San Antonio</publisher-loc>
<publisher-name>Pearson</publisher-name>
</element-citation>
</ref>
<ref id="CR50">
<label>50.</label>
<element-citation publication-type="book">
<person-group person-group-type="author">
<name>
<surname>Wechsler</surname>
<given-names>D</given-names>
</name>
</person-group>
<source/>Preschool and Primary Scale of Intelligence
          <year>2002</year>
<edition>3</edition>
<publisher-loc>San Antonio</publisher-loc>
<publisher-name>The Psychological Corporation</publisher-name>
</element-citation>
</ref>
<ref id="CR51">
<label>51.</label>
<element-citation publication-type="book">
<person-group person-group-type="author">
<name>
<surname>Sparrow</surname>
<given-names>SS</given-names>
</name>
<name>
<surname>Cicchetti</surname>
<given-names>DV</given-names>
</name>
<name>
<surname>Balla</surname>
<given-names>DA</given-names>
</name>
</person-group>
<source/>Vineland Adaptive Behavior Scales: Second edition (Vineland II), Survey Forms Manual
          <year>2005</year>
<publisher-loc>Livonia</publisher-loc>
<publisher-name>Pearson</publisher-name>
</element-citation>
</ref>
<ref id="CR52">
<label>52.</label>
<element-citation publication-type="book">
<person-group person-group-type="author">
<name>
<surname>Dunn</surname>
<given-names>LM</given-names>
</name>
<name>
<surname>Dunn</surname>
<given-names>DM</given-names>
</name>
</person-group>
<source/>Peabody Picture Vocabulary Test, Fourth Edition (PPVT-4), Manual
          <year>2007</year>
<publisher-loc>Minneapolis</publisher-loc>
<publisher-name>Pearson</publisher-name>
</element-citation>
</ref>
<ref id="CR53">
<label>53.</label>
<element-citation publication-type="book">
<person-group person-group-type="author">
<name>
<surname>Williams</surname>
<given-names>KT</given-names>
</name>
</person-group>
<source/>The Expressive Vocabulary Test, Second Edition (EVT-2), Manual
          <year>2007</year>
<publisher-loc>Minneapolis</publisher-loc>
<publisher-name>Pearson</publisher-name>
</element-citation>
</ref>
<ref id="CR54">
<label>54.</label>
<element-citation publication-type="book">
<person-group person-group-type="author">
<name>
<surname>Beery</surname>
<given-names>KE</given-names>
</name>
<name>
<surname>Beery</surname>
<given-names>NA</given-names>
</name>
</person-group>
<source/>The Beery-Buktenica Developmental Test of Visual-Motor Integration, Sixth Edition (Beery VMI), Administration, Scoring, and Teaching Manual
          <year>2010</year>
<publisher-loc>Bloomington</publisher-loc>
<publisher-name>Pearson</publisher-name>
</element-citation>
</ref>
<ref id="CR55">
<label>55.</label>
<element-citation publication-type="book">
<person-group person-group-type="author">
<name>
<surname>Wilson</surname>
<given-names>BN</given-names>
</name>
<name>
<surname>Dewey</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Campbell</surname>
<given-names>A</given-names>
</name>
</person-group>
<source/>Developmental coordination disorder questionnaire (DCDQ)
          <year>1998</year>
<publisher-loc>Canada</publisher-loc>
<publisher-name>Alberta Children’s Hospital Research Center</publisher-name>
</element-citation>
</ref>
<ref id="CR56">
<label>56.</label>
<element-citation publication-type="book">
<person-group person-group-type="author">
<name>
<surname>Achenbach</surname>
<given-names>TM</given-names>
</name>
<name>
<surname>Edelbrock</surname>
<given-names>CS</given-names>
</name>
<name>
<surname>Rescorla</surname>
<given-names>LA</given-names>
</name>
</person-group>
<source/>Manual for ASEBA School-Age Forms &amp; Profiles
          <year>2001</year>
</element-citation>
</ref>
<ref id="CR57">
<label>57.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Aman</surname>
<given-names>MG</given-names>
</name>
<name>
<surname>Singh</surname>
<given-names>NN</given-names>
</name>
<name>
<surname>Stewart</surname>
<given-names>AW</given-names>
</name>
<name>
<surname>Field</surname>
<given-names>CJ</given-names>
</name>
</person-group>
<article-title>The aberrant behavior checklist: a behavior rating scale for the assessment of treatment effects</article-title>
<source/>Am J Ment Defic
          <year>1985</year>
<volume>89</volume>
<fpage>485</fpage>
<lpage>491</lpage>
<pub-id pub-id-type="pmid">3993694</pub-id>
</element-citation>
</ref>
<ref id="CR58">
<label>58.</label>
<element-citation publication-type="book">
<person-group person-group-type="author">
<name>
<surname>Aman</surname>
<given-names>MG</given-names>
</name>
<name>
<surname>Singh</surname>
<given-names>NN</given-names>
</name>
</person-group>
<source/>Aberrant Behavior Checklist (ABC) Manual
          <year>1986</year>
<publisher-loc>East Aurora</publisher-loc>
<publisher-name>Slosson Educational Publications, Inc</publisher-name>
</element-citation>
</ref>
<ref id="CR59">
<label>59.</label>
<element-citation publication-type="book">
<person-group person-group-type="author">
<name>
<surname>Aman</surname>
<given-names>MG</given-names>
</name>
<name>
<surname>Singh</surname>
<given-names>NN</given-names>
</name>
</person-group>
<source/>Aberrant Behavior Checklist-Community (ABC), Supplementary Manual
          <year>1994</year>
<publisher-loc>East Aurora</publisher-loc>
<publisher-name>Slosson Educational Publications, Inc</publisher-name>
</element-citation>
</ref>
<ref id="CR60">
<label>60.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Reuter</surname>
<given-names>MS</given-names>
</name>
<name>
<surname>Riess</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Moog</surname>
<given-names>U</given-names>
</name>
<name>
<surname>Briggs</surname>
<given-names>TA</given-names>
</name>
<name>
<surname>Chandler</surname>
<given-names>KE</given-names>
</name>
<name>
<surname>Rauch</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Stampfer</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Steindl</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Glaser</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Joset</surname>
<given-names>P</given-names>
</name>
<etal></etal>
</person-group>
<article-title>FOXP2 variants in 14 individuals with developmental speech and language disorders broaden the mutational and clinical spectrum</article-title>
<source/>J Med Genet
          <year>2017</year>
<volume>54</volume>
<fpage>64</fpage>
<lpage>72</lpage>
<pub-id pub-id-type="doi">10.1136/jmedgenet-2016-104094</pub-id>
<pub-id pub-id-type="pmid">27572252</pub-id>
</element-citation>
</ref>
<ref id="CR61">
<label>61.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vernes</surname>
<given-names>SC</given-names>
</name>
<name>
<surname>Nicod</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Elahi</surname>
<given-names>FM</given-names>
</name>
<name>
<surname>Coventry</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Kenny</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Coupe</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Bird</surname>
<given-names>LE</given-names>
</name>
<name>
<surname>Davies</surname>
<given-names>KE</given-names>
</name>
<name>
<surname>Fisher</surname>
<given-names>SE</given-names>
</name>
</person-group>
<article-title>Functional genetic analysis of mutations implicated in a human speech and language disorder</article-title>
<source/>Hum Mol Genet
          <year>2006</year>
<volume>15</volume>
<fpage>3154</fpage>
<lpage>3167</lpage>
<pub-id pub-id-type="doi">10.1093/hmg/ddl392</pub-id>
<pub-id pub-id-type="pmid">16984964</pub-id>
</element-citation>
</ref>
<ref id="CR62">
<label>62.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lam</surname>
<given-names>KS</given-names>
</name>
<name>
<surname>Aman</surname>
<given-names>MG</given-names>
</name>
</person-group>
<article-title>The Repetitive Behavior Scale-Revised: independent validation in individuals with autism spectrum disorders</article-title>
<source/>J Autism Dev Disord
          <year>2007</year>
<volume>37</volume>
<fpage>855</fpage>
<lpage>866</lpage>
<pub-id pub-id-type="doi">10.1007/s10803-006-0213-z</pub-id>
<pub-id pub-id-type="pmid">17048092</pub-id>
</element-citation>
</ref>
<ref id="CR63">
<label>63.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chang</surname>
<given-names>SW</given-names>
</name>
<name>
<surname>Mislankar</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Misra</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Dajusta</surname>
<given-names>DG</given-names>
</name>
<name>
<surname>Harrison</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>McBride</surname>
<given-names>KL</given-names>
</name>
<name>
<surname>Baker</surname>
<given-names>LA</given-names>
</name>
<name>
<surname>Garg</surname>
<given-names>V</given-names>
</name>
</person-group>
<article-title>Genetic abnormalities in FOXP1 are associated with congenital heart defects</article-title>
<source/>Hum Mutat
          <year>2013</year>
<volume>34</volume>
<fpage>1226</fpage>
<lpage>1230</lpage>
<pub-id pub-id-type="doi">10.1002/humu.22366</pub-id>
<pub-id pub-id-type="pmid">23766104</pub-id>
</element-citation>
</ref>
<ref id="CR64">
<label>64.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Homsy</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Zaidi</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Shen</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Ware</surname>
<given-names>JS</given-names>
</name>
<name>
<surname>Samocha</surname>
<given-names>KE</given-names>
</name>
<name>
<surname>Karczewski</surname>
<given-names>KJ</given-names>
</name>
<name>
<surname>DePalma</surname>
<given-names>SR</given-names>
</name>
<name>
<surname>McKean</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Wakimoto</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Gorham</surname>
<given-names>J</given-names>
</name>
<etal></etal>
</person-group>
<article-title>De novo mutations in congenital heart disease with neurodevelopmental and other congenital anomalies</article-title>
<source/>Science
          <year>2015</year>
<volume>350</volume>
<fpage>1262</fpage>
<lpage>1266</lpage>
<pub-id pub-id-type="doi">10.1126/science.aac9396</pub-id>
<pub-id pub-id-type="pmid">26785492</pub-id>
</element-citation>
</ref>
<ref id="CR65">
<label>65.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Weidenfeld</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>MM</given-names>
</name>
<name>
<surname>Maika</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Kuziel</surname>
<given-names>WA</given-names>
</name>
<name>
<surname>Morrisey</surname>
<given-names>EE</given-names>
</name>
<name>
<surname>Tucker</surname>
<given-names>PW</given-names>
</name>
</person-group>
<article-title>Foxp1 regulates cardiac outflow tract, endocardial cushion morphogenesis and myocyte proliferation and maturation</article-title>
<source/>Development
          <year>2004</year>
<volume>131</volume>
<fpage>4477</fpage>
<lpage>4487</lpage>
<pub-id pub-id-type="doi">10.1242/dev.01287</pub-id>
<pub-id pub-id-type="pmid">15342473</pub-id>
</element-citation>
</ref>
<ref id="CR66">
<label>66.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rocca</surname>
<given-names>DL</given-names>
</name>
<name>
<surname>Wilkinson</surname>
<given-names>KA</given-names>
</name>
<name>
<surname>Henley</surname>
<given-names>JM</given-names>
</name>
</person-group>
<article-title>SUMOylation of FOXP1 regulates transcriptional repression via CtBP1 to drive dendritic morphogenesis</article-title>
<source/>Sci Rep
          <year>2017</year>
<volume>7</volume>
<fpage>877</fpage>
<pub-id pub-id-type="doi">10.1038/s41598-017-00707-6</pub-id>
<pub-id pub-id-type="pmid">28408745</pub-id>
</element-citation>
</ref>
<ref id="CR67">
<label>67.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fujita</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Tanabe</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Shiota</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Ueda</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Suwa</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Momoi</surname>
<given-names>MY</given-names>
</name>
<name>
<surname>Momoi</surname>
<given-names>T</given-names>
</name>
</person-group>
<article-title>Ultrasonic vocalization impairment of Foxp2 (R552H) knockin mice related to speech-language disorder and abnormality of Purkinje cells</article-title>
<source/>Proc Natl Acad Sci U S A
          <year>2008</year>
<volume>105</volume>
<fpage>3117</fpage>
<lpage>3122</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.0712298105</pub-id>
<pub-id pub-id-type="pmid">18287060</pub-id>
</element-citation>
</ref>
<ref id="CR68">
<label>68.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Banham</surname>
<given-names>AH</given-names>
</name>
<name>
<surname>Beasley</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Campo</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Fernandez</surname>
<given-names>PL</given-names>
</name>
<name>
<surname>Fidler</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Gatter</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Jones</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Mason</surname>
<given-names>DY</given-names>
</name>
<name>
<surname>Prime</surname>
<given-names>JE</given-names>
</name>
<name>
<surname>Trougouboff</surname>
<given-names>P</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The FOXP1 winged helix transcription factor is a novel candidate tumor suppressor gene on chromosome 3p</article-title>
<source/>Cancer Res
          <year>2001</year>
<volume>61</volume>
<fpage>8820</fpage>
<lpage>8829</lpage>
<pub-id pub-id-type="pmid">11751404</pub-id>
</element-citation>
</ref>
</ref-list>
</back>
</article>
</pmc-articleset>